

1 **The *Borrelia burgdorferi* adenylyl cyclase, CyaB, is important for**
2 **virulence factor production and mammalian infection**

3 Running Title: CyaB role in borrelial pathogenesis

4 **Vanessa M. Ante¹, Lauren C. Farris¹, Elizabeth P. Saputra¹, Allie J. Hall², Nathaniel S.**
5 **O'Bier³, Adela S. Oliva Chavez⁴, Richard T. Marconi³, Meghan C. Lybecker², and Jenny A.**
6 **Hyde^{1*}**

7 ¹ Texas A&M University Health Science Center, Department of Microbial Pathogenesis and
8 Immunology, Bryan, TX, USA

9 ² University of Colorado at Colorado Springs, Department of Biology, Colorado Springs, CO, USA

10 ³ Virginia Commonwealth University Medical Center, Department of Microbiology and
11 Immunology, Richmond, VA, USA

12 ⁴ Texas A&M University, Department of Entomology, College Station, TX, USA

13 *** Correspondence:**
14 Jenny Hyde, Ph.D.
15 jhyde@tamu.edu

16 **Key words: CyaB, adenylate cyclase, *Borrelia burgdorferi*, cAMP, small RNA, cyclic**
17 **nucleotides, Lyme disease, and secondary messenger**

18 **Abstract.**

19 *Borrelia burgdorferi*, the causative agent of Lyme disease, traverses through vastly distinct
20 environments between the tick vector and the multiple phases of the mammalian infection that
21 requires genetic adaptation for the progression of pathogenesis. Borrelial gene expression is highly
22 responsive to changes in specific environmental signals that initiate the RpoS regulon for
23 mammalian adaptation, but the mechanism(s) for direct detection of environmental cues has yet to
24 be identified. Secondary messenger cyclic adenosine monophosphate (cAMP) produced by
25 adenylate cyclase is responsive to environmental signals, such as carbon source and pH, in many
26 bacterial pathogens to promote virulence by altering gene regulation. *B. burgdorferi* encodes a
27 single non-toxin class IV adenylate cyclase (*bb0723*, *cyaB*). This study investigates *cyaB*
28 expression along with its influence on borrelial virulence regulation and mammalian infectivity.
29 Expression of *cyaB* was specifically induced with co-incubation of mammalian host cells that was
30 not observed with cultivated tick cells suggesting that *cyaB* expression is influenced by cellular
31 factor(s) unique to mammalian cell lines. The 3' end of *cyaB* also encodes a small RNA, SR0623,
32 in the same orientation that overlaps with *bb0722*. The differential processing of *cyaB* and SR0623
33 transcripts may alter the ability to influence function in the form of virulence determinant
34 regulation and infectivity. Two independent *cyaB* deletion B31 strains were generated in 5A4-NP1
35 and ML23 backgrounds and complemented with the *cyaB* ORF alone that truncates SR0623, *cyaB*
36 with intact SR0623, or *cyaB* with a mutagenized full length SR0623 to evaluate the influence on
37 transcriptional and post-transcriptional regulation of borrelial virulence factors and infectivity. In
38 the absence of *cyaB*, expression and production of *ospC* was significantly reduced, while the
39 protein levels for BosR and DbpA were substantially lower than parental strains. Infectivity studies
40 with both independent *cyaB* mutants demonstrated an attenuated phenotype with reduced
41 colonization of tissues during early disseminated infection. This work suggests that *B. burgdorferi*
42 utilizes *cyaB* and potentially cAMP as a regulatory pathway to modulate borrelial gene expression
43 and protein production to promote borrelial virulence and dissemination in the mammalian host.

44

45 Introduction.

46 *Borrelia burgdorferi*, the causative agent of Lyme disease, is an emerging infectious
47 disease that causes a robust inflammatory multistage disease and accounts for over 80% of all
48 vector-borne illnesses in the United States (Rosenberg 2018; Radolf et al. 2012; Stanek and Strle
49 2018; Steere et al. 2016). Localized disease presents as flu-like symptoms and is frequently
50 associated with an erythema migrans “bull’s-eye” rash (Steere et al. 2016; Stanek and Strle 2018).
51 If left untreated, the pathogen disseminates to specific tissues with systemic symptoms developing
52 including arthritis, carditis, and encephalomyelitis (Hu 2016; Steere et al. 2016; Stanek and Strle
53 2018). Patients experience severe morbidity due to ongoing fatigue and malaise as a result of the
54 inflammatory response elicited by *B. burgdorferi*. To date, no human vaccine is available and
55 therapeutics for late stage disease are limited.

56 *B. burgdorferi* lacks classically-defined virulence factors, such as secretion systems and
57 toxins, and instead relies on dynamic genetic regulation and antigenic variability to invade multiple
58 tissue types and evade the immune system (Radolf et al. 2012; D. Scott Samuels and Samuels
59 2016). Many studies have noted the responsiveness of *B. burgdorferi* to environmental signals,
60 such as temperature, pH, O₂, CO₂, and osmotic stress, as it travels from the tick vector to the
61 mammalian host, but mechanisms of direct environmental detection remain unknown (Carroll,
62 Garon, and Schwan 1999; Carroll, Cordova, and Garon 2000; Popitsch et al. 2017; Konkel and
63 Tilly 2000; Stevenson, Schwan, and Rosa 1995; Tokarz et al. 2004; Seshu, Boylan, Gherardini, et
64 al. 2004; Hyde, Trzeciakowski, and Skare 2007; Bontemps-Gallo, Lawrence, and Gherardini 2016;
65 X. Yang et al. 2000). The BosR-RpoN-Rrp2-RpoS signaling cascade responds to changing
66 environmental cues to allow borrelial adaptation during early mammalian infection and resistance
67 to innate immunity by altering the outer membrane lipoprotein composition (Hyde et al. 2009;
68 Zhiming Ouyang, Deka, and Norgard 2011; Jon S. Blevins et al. 2009; Hyde et al. 2010; Zhiming
69 Ouyang et al. 2009; Z. Ouyang, Blevins, and Norgard 2008; A. H. Smith et al. 2007; M. J. Caimano
70 et al. 2007; 2004; Melissa J. Caimano et al. 2019). Transcription of *rpoS* is regulated by a
71 transcription complex formed of the RNA polymerase, the sigma factor RpoN, the phosphorylated
72 Response regulator protein (Rrp2), and the *Borrelia* oxidative stress regulator (BosR) (Xiaofeng
73 F. Yang, Alani, and Norgard 2003; Jon S. Blevins et al. 2009; Hyde et al. 2009; Zhiming Ouyang,
74 Deka, and Norgard 2011; Hyde et al. 2010; Zhiming Ouyang et al. 2009; A. H. Smith et al. 2007).
75 The borrelial RpoS regulon includes outer surface lipoproteins DbpA, OspC, and BBK32, and
76 other factors important for tick to mouse transmission and survival in mammalian hosts (He et al.
77 2007, 32; Hübner et al. 2001; Melissa J. Caimano et al. 2005; 2007; X. F. Yang et al. 2005).

78 Secondary messengers are a mechanism used by bacterial pathogens, such as *B.*
79 *burgdorferi*, to modulate gene expression and post-transcriptional regulation in response to
80 environmental signals by altering the function of bound proteins (Yin et al. 2020; Purificação et
81 al. 2020; McDonough and Rodriguez 2011; Savage et al. 2015; Ye et al. 2014; Rogers et al. 2009).
82 In *B. burgdorferi*, the second messenger cyclic di-adenosine monophosphate (c-di-AMP) is
83 essential for in vitro growth and the production of mammalian virulence factors (Ye et al. 2014;
84 Savage et al. 2015). Cyclic di-guanosine monophosphate (c-di-GMP) is a key component of the
85 Hk1-Rrp1 two-component system pathway involved in mammal to tick transmission, midgut
86 survival, motility, and glycerol utilization by *B. burgdorferi* (Zhang et al. 2018; Novak, Sultan,
87 and Motaleb 2014; He et al. 2011; Sultan et al. 2011; Bontemps-Gallo, Lawrence, and Gherardini
88 2016; Melissa J. Caimano et al. 2015). c-di-GMP is produced by Rrp1 and bound by PlzA to

89 positively regulate glucose metabolism (Rogers et al. 2009; Freedman et al. 2010; Kostick-Dunn
90 et al. 2018; Kostick et al. 2011; Mallory et al. 2016; Sultan et al. 2010; He et al. 2014). Another
91 second messenger cyclic adenosine monophosphate (cAMP) has received less attention in *B.*
92 *burgdorferi*, but has been found to support virulence in other pathogenic bacteria (McDonough
93 and Rodriguez 2011). cAMP is generated by adenylate cyclases (ACs) to modulate regulation of
94 the bacteria or the host cell depending on which of the 6 classes of AC. cAMP can bind to cAMP
95 receptor proteins (CRP) often resulting in a conformation change that promote efficient binding of
96 specific DNA sites and transcription of numerous genes. *B. burgdorferi* encodes a single class IV
97 AC (*bb0723*), annotated as *cyaB*, which is the smallest of the classes, highly thermostable, and has
98 been identified in only 3 other bacterial species (Khajanchi et al. 2016; Gallagher et al. 2006; N.
99 Smith et al. 2006; Casjens et al. 2000; Dong et al. 2013; Sismeiro et al. 1998). The borrelial genome
100 lacks an annotated CRP or cAMP phosphodiesterase, therefore it is unclear how *B. burgdorferi*
101 generated cAMP might modulate the pathogenesis-specific regulation (Casjens et al. 2000). A
102 previous study confirmed the AC enzymatic activity of recombinant borrelial CyaB (Khajanchi et
103 al. 2016). During infection studies with a transposon *cyaB* mutant strain, it was found that *cyaB*
104 did not play a role in tick to mouse transmission or mammalian infectivity when examined
105 qualitatively by culture outgrowth. A borrelial Tn-seq identified *cyaB* as contributing to resistance
106 to oxidative stress (Ramsey et al. 2017). The overall function of the CyaB enzyme in *B. burgdorferi*
107 signal transduction and virulence factor regulation remains unclear, especially in the absence of
108 any detectable downstream effector molecules that would recognize cAMP.

109 Borrelial *cyaB* overlaps with an intragenic small RNA (sRNA) SR0623 at the 3' end of the
110 open reading frame (ORF) and extends into the neighboring *bb0722* gene (Popitsch et al. 2017).
111 sRNAs can be arranged in the genome as antisense, 5' and 3' untranslated region (UTR), intergenic,
112 or intragenic (Gottesman and Storz 2011; Papenfort and Vogel 2010; Babitzke et al. 2019). sRNAs
113 have a broad range of function with the ability to regulate translation of target mRNA, degradation
114 of target mRNA, act as a riboswitch, or bind to proteins either altering or sequestering their
115 activity. Recent sRNA transcriptome studies identified over 1,000 putative borrelial sRNA that are
116 regulated in response to temperature shift and nutrient stress (Popitsch et al. 2017; Drecktrah et al.
117 2018).

118 In this study, we investigated the role of *cyaB* and SR0623 in borrelial pathogenesis. Our
119 findings indicate that *cyaB* influences mammalian virulence in part through regulation of the
120 BosR-RpoN-Rrp2-RpoS pathway. The regulation of *cyaB* was specific to interactions with host
121 cells, further suggesting this AC is important for the mammalian cycle of pathogenesis and may
122 be responsive to unique host specific signals. CyaB, and possible cAMP signaling, has the potential
123 to be an uncharacterized signaling and regulation pathway important for the progression of Lyme
124 disease.

125 **Materials and methods.**

126 **Growth conditions and media.**

127 *E. coli* was grown in Luria-Bertani (LB) broth supplemented with antibiotics at the
128 following concentrations: kanamycin 50µg/ml, spectinomycin 100µg/ml, or gentamicin 15µg/ml.
129 *B. burgdorferi* was grown in Barbour-Stoener-Kelly II (BSKII) medium supplemented with 6%
130 normal rabbit serum (NRS) under microaerophilic conditions at 32°C with 1% CO₂ unless
131 otherwise stated (Barbour 1984). Modified BSK lacks bovine serum albumin (BSA), pyruvate,
132 and NRS (Ramsey et al. 2017). BSK-lite was made using CMRL 1066 without L-glutamine and
133 without glucose (USBiological) supplemented with 6% NRS and 0.01% L-glutamine (von Lackum
134 and Stevenson 2005). BSK-glycerol is BSK-lite with 0.6% glycerol. BSK media was
135 supplemented with antibiotics at the following concentrations: kanamycin 300µg/ml, streptomycin
136 100µg/ml, or gentamicin 50µg/ml.

137 **Plasmid construction and strain generation.**

138 Strains, plasmids, and primers generated in this study are listed in Table 1 & S1,
139 respectively. The *cyaB* (*bb0723*) deletion construct was generated by amplifying upstream and
140 downstream regions of approximately 1.5kb and individually TOPO cloned into pCR8
141 (ThermoFisher) resulting in pJH380 and pJH381, respectively. A KpnI and BamI digest inserted
142 the downstream region from pJH381 into pJH380 to generate pJH383. The *P_{f_lgB}*-*aadA* was PCR
143 amplified and cloned into pCR2.1, designated pJH431, and cloned into pJH383 by SphI and KpnI
144 digest generating the final deletion construct, pJH432. This final construct was transformed into
145 *B. burgdorferi* ML23 and 5A4-NP1, resulting in JH441 and JH522, respectively (Figure 1)
146 (Labandeira-Rey and Skare 2001; Lawrenz et al. 2002). A chromosomal *cyaB* complement
147 construct, pJH446, was generated in the pJH333 backbone that encodes 1.5kb chromosomal
148 regions to allow allelic exchange between *bb0445* and *bb0446*, using *P_{f_lgB}*-*aacC1* as the antibiotic
149 selection (Li et al. 2007; Hyde, Weening, and Skare 2011). JH441 was transformed with pJH446
150 resulting in strain JH446. The mutant and chromosomal complement strains were transformed with
151 pBBE22*luc* to introduce constitutively expressed bioluminescence (J. S. Blevins et al. 2007; Hyde
152 et al. 2011).

153 A similar construct, pVA110, was generated by amplifying the upstream *bb0445* fragment
154 and *P_{f_lgB}*-*aacC1* using primers *bb0445*-F-BamHI/*bb0445*-R and *P_{f_lgB}*-F-NotI/gent-R, respectively
155 and underwent overlap PCR with *bb0445*-F-BamHI and *P_{f_lgB}*-F-NotI, digested with BamHI and
156 NotI, and cloned into pJH333. The *cyaB* complement fragment *cyaB* with SR0623 was PCR
157 amplified using the indicated primers in Table S1, digested with NotI and XhoI, and ligated into
158 pENTR1a-N3xFLAG (ThermoFisher) to create plasmid pVA85. The complement fragment *cyaB*
159 ORF was PCR amplified using primers *P_{cyaB}*-F-SalI/*P_{cyaB}*-R and *cyaB*ORF-F/*cyaB*ORF-R-SalI
160 with pVA85 as the template and underwent overlap PCR with *P_{cyaB}*-F-SalI and *cyaB*ORF-R-SalI.
161 The complement fragment *cyaB* with SR0623 was amplified using primer pair *P_{cyaB}*-F-
162 SalI/*P_{cyaB}*-R and *cyaB*ORF-F/*cyaB*SR0623-R-SalI with pVA85 as the template and underwent
163 overlap PCR with *P_{cyaB}*-F-SalI and *cyaB*SR0623-R-SalI. The modified SR0623 sequence was
164 engineer and manufactured by GenScript to alter the wobble base pair throughout the sRNA
165 (Figure S1). The complement fragments were cloned into pVA110 using the SalI restriction sites

166 resulting in pVA112, pVA114, and pVA146, respectively. Chromosomal complement plasmids
167 were transformed into JH522 generating VA200, VA272, and VA336 (Figure 1 & Table 1).

168 To make a *trans* inducible FLAG tagged *cydB* complement with gentamicin resistance for
169 overproduction of CyaB, the NdeI site from P_{flgB}-*aacCI* was removed by amplifying the P_{flgB} and
170 the *aacCI* cassette with pBSV2G as the template. An overlap PCR was performed on the P_{flgB} and
171 the *aacCI* PCR products, digested, and ligated into pJSB268 digested with AatII and BglII and
172 blunt ended by Klenow (New England Biolabs) to create plasmid pVA87. To generate a N-
173 terminally FLAG tagged *cydB* construct (pVA102), *cydB* was amplified from pVA85, digested
174 with NdeI and HindIII, and ligated into pVA87. JH522 was transformed with pVA102.

175 Electroporation of plasmid DNA into *B. burgdorferi* was done as previously described (D
176 S Samuels, Mach, and Garon 1994; Hyde, Weening, and Skare 2011). Up to 60µg of DNA was
177 transformed, recovered overnight, and then selected for by limiting dilution liquid plating in the
178 appropriate antibiotic and 0.5% phenol red. Transformants were PCR screened for both the allelic
179 exchange and plasmid content (Labandeira-Rey and Skare 2001).

180 **Oxidative stress assays.**

181 Sensitivity to the oxidative stressor H₂O₂ was determined as previously performed (Hyde
182 et al. 2009; Ramsey et al. 2017). Briefly, *B. burgdorferi* was grown in BSK-glycerol to mid-log
183 phase, pelleted at 4,800xg for 10 min at 4°C, washed with 1X phosphate buffered saline (PBS),
184 and resuspended in modified BSK. 5x10⁷ cells were treated with or without H₂O₂, and incubated
185 at 32°C 1% CO₂ for 4 hours in a 1ml volume. Samples were centrifuged at 6,600xg for 10 min at
186 4°C, resuspended in BSKII with 6% NRS and 0.6% phenol red, serial diluted in 96-well plates,
187 and incubated for 14 days to assess media color change and survival. Survival was measured from
188 three biological replicates and the data was converted to logarithmic values before calculating the
189 averages.

190 ***B. burgdorferi* co-cultivation assays.**

191 *B. burgdorferi* was co-incubated with *Ixodes scapularis* embryonic cell line ISE6 and
192 human neuroglioma cell line H4 (ATCC HTB-148) to evaluate bacterial transcriptional changes
193 (Schmit, Patton, and Gilmore 2011; J. H. Oliver et al. 1993). ISE6 was maintained in L15C300
194 supplemented media at 34°C 2% CO₂ in 25 cm² flasks seeded with 1x10⁷ cells (90% confluency)
195 for 24 hours (J. D. Oliver et al. 2015). H4 cells were seeded at 90% confluency in Dulbecco's
196 modified Eagle's medium (DMEM) (Sigma) supplemented with 10% FetalPlex (GeminiBio),
197 herein designated DMEM+, at 37°C 5% CO₂ for 17 hours. *B. burgdorferi* was grown to mid-log
198 phase under the same conditions as the cell line, cells were pelleted, washed in PBS, and
199 resuspended in cell culture media. *B. burgdorferi* were added to the ISE6 and H4 cells at a
200 multiplicity of infection (MOI) of 10 and 40, respectively (Livengood, Schmit, and Gilmore 2008;
201 J. H. Oliver et al. 1993). Equivalent numbers of borrelial cells were incubated in cell culture media
202 alone as a control. At 3, 6, and 24 hours post infection, the cultivation media was collected for
203 RNA isolation and qRT-PCR analysis.

204 **Western analysis.**

205 *B. burgdorferi* were grown in BSK-lite or BSK-glycerol to mid-log phase and cell lysates
206 were resolved on a 12.5% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
207 PAGE), transferred to a polyvinylidene difluoride (PVDF) membrane, and western
208 immunoblotting was conducted as previously described (Labandeira-Rey and Skare 2001; Saputra,
209 Trzeciakowski, and Hyde 2020). Antibody was generated in Sprague-Dawley rats against PlzA as
210 previously described (D. P. Miller et al. 2016; Izac et al. 2019). The following primary antibody
211 concentrations were used: mouse anti-flagellum (1:4000) (Affinity Bioreagent), mouse anti-FLAG
212 (1:4000) (Sigma), rabbit anti-P66 (1:5000) (Cugini et al. 2003), rabbit anti-BosR (1:1000) (Seshu,
213 Boylan, Hyde, et al. 2004), rabbit anti-DbpA (1:10000) (Guo et al. 1998), rat anti-PlzA (1:1000),
214 mouse anti-BadR (1:1000) (C. L. Miller, Karna, and Seshu 2013), mouse anti-OspC (1:20000) (He
215 et al. 2014), mouse-anti-OspA (1:1000) (Capricorn), and mouse anti-Rrp2 (1:1000) (Xiaofeng F.
216 Yang, Alani, and Norgard 2003). Secondary antibodies were coupled to horseradish peroxidase
217 (HRP): donkey-anti-rabbit IgG HRP (Amersham), goat-anti-mouse IgG HRP (ThermoFisher), and
218 rabbit-anti-rat IgG HRP (ThermoFisher). Membranes were imaged with chemiluminescent
219 substrates to detect antigen-antibody complexes. The immunoblot data presented is representative
220 of at least three biological replicates.

221 **Reverse transcriptase PCR (RT-PCR) and quantitative RT-PCR (qRT-PCR).**

222 *B. burgdorferi* RNA was isolated using hot phenol chloroform extraction as previously
223 described (Meghan Lybecker et al. 2014; M. Lybecker and Henderson 2018). Total RNA was
224 treated with DNaseI (Roche) and 1µg was converted to cDNA using Super Script III reverse
225 transcriptase (+RT) (ThermoFisher) according to the manufacturer’s instructions. A no RT control
226 was included for each RNA sample. PCR reactions using 500ng cDNA as template were amplified
227 with AccuStart II PCR Supermix (Quantabio) and imaged on a 1% agarose gel. qRT-PCR reactions
228 were performed from in vitro cultivated samples with 50ng +RT and –RT cDNA using a ViiA 7
229 Real-Time PCR system (Applied Biosystems) and Fast SYBR Green Master Mix (Applied
230 Biosystems) according to the manufacturer’s instructions. *B. burgdorferi* co-cultures transcript
231 experiments were performed using PerfeCTa SYBR Green FastMix ROX (Quantabio) and
232 StepOnePlus Real-Time PCR system (Applied Biosystems). *flaB* was used as an internal control
233 and fold change relative to wild type (WT) calculated using the $2^{-\Delta\Delta CT}$ method from three to four
234 biological and technical replicates (Livak and Schmittgen 2001).

235 **Northern blots.**

236 RNA was collected from *B. burgdorferi* strains grown in BSK-glycerol to mid-log phase
237 at 32°C 1%CO₂. RNA isolation and Northern blot analysis was performed as previously described
238 (Popitsch et al. 2017). 7-10 µg of RNA was denatured in 2x RNA load dye (Thermofisher) and
239 heated to 65°C for 15 min, loaded on to a Novex Pre-cast 6% TBE-Urea (8M) polyacrylamide gel
240 (Thermofisher) in 1X TBE and run for 45-60 min. RNA was electroblotted at room temperature
241 (10V for 1 h in 0.5X TBE) to HybondXL membranes (Amersham). The membranes were UV
242 cross-linked (Fisher Scientific UV Crosslinker FB-UVXL-1000) and probed with DNA
243 oligonucleotide (Table S1) in OligoHyb buffer (Thermofisher) per the manufacturer’s protocol.
244 Oligonucleotide probes were end-labeled with γ -³²P ATP (Perkin-Elmer) and T4 PNK (New
245 England Biolabs) per the manufacturer’s instructions. Unincorporated P³² was removed using

246 illustra™ MicroSpin™ G50 columns (GE healthcare). Purified probes were heated at 95°C for 5
247 min before being added to the prehybridizing bots. Blots were hybridized at 42°C rotating
248 overnight. Membranes were washed 2x 30 min in wash buffer (2x SSC 0.1% SDS). Membranes
249 were placed on Kodiak BioMax maximum sensitivity (MS) autoradiography film and placed in
250 the -80°C for 1-10 days depending on the radiation emission given by each membrane. Film was
251 developed on an AFP imaging developer and scanned using an Epson Expression 10000XL. 5S
252 rRNA was used as the loading control. The Northern blot data presented is representative of three
253 biological replicates.

254 **Mouse infection studies.**

255 Infection studies were conducted using 6-8 week-old C3H/HeN female mice (Charles
256 Rivers) with 5A4-NP1, JH522, VA200, VA272, or VA336. Four to five mice were infected with
257 10^5 *B. burgdorferi* by ventral intradermal (ID) injection. Mice were sacrificed and tissues
258 aseptically collected at 7, 14, and 21 days post infection (dpi) for cultivation or qPCR of borrelial
259 load. Outgrowth of viable *B. burgdorferi* was determined by dark-field microscopy and the percent
260 positive tissues was determined. Mice tissues were harvested and DNA was isolated using the
261 DNeasy Blood & Tissue kit (Qiagen) according to the manufacturer's instructions with the
262 addition 40µl of 10% collagenase (Sigma) and incubated at 55°C overnight. qPCR reactions were
263 performed using a StepOnePlus Real-Time PCR system (Applied Biosystems) and PowerUp
264 SYBR Green Master Mix (Applied Biosystems) according to the manufacturer's instructions.
265 Standard curves were used to determine the absolute quantification of mouse β -actin and *B.*
266 *burgdorferi recA*. Technical triplicates were measured for each sample and values are displayed
267 as copies of *B. burgdorferi recA* per 10^6 mouse β -actin.

268 To spatially and temporally track luminescent *B. burgdorferi* during infection, an in vivo
269 imaging system (IVIS) was used to image mice (IVIS Spectrum, Perkin Elmer). IVIS infection
270 studies were conducted using 6-8 week-old Balb/c female mice (Charles Rivers) as previously
271 described (Hyde et al. 2011; Hyde and Skare 2018). Briefly, groups of 5 mice were ID infected
272 with 10^5 *B. burgdorferi* strain ML23 pBBE22*luc*, JH441 pBBE22*luc*, or JH446 pBBE22*luc*. Mice
273 were intraperitoneally (IP) treated with 5mg of D-luciferin and imaged at 1 hour, 1, 4, 7, 10, 14,
274 and 21 dpi. One infected mouse of each group did not receive D-luciferin to serve as a negative
275 control for background luminescence. Images were collected with 1 and 10 min exposures and
276 bioluminescence from the whole body quantitated. Images in the 600-60,000 counts range were
277 used to quantitate bioluminescence. Background bioluminescence was subtracted from the treated
278 samples and averaged. Mice were sacrificed 21 dpi and harvested tissues were used for cultivation
279 as described above.

280 **Animal ethics statement.**

281 Texas A&M University is accredited by the Association for Assessment and Accreditation
282 of Laboratory Animal Care (AAALAC) indicating their commitment to responsible animal care
283 and use. All animal experiments were performed in accordance with the Guide for Care and Use
284 of Laboratory Animals provided by the National Institute of Health (NIH) and the Guidelines of
285 the Approval for Animal Procedures provided by the Institutional Animal Care and Use Committee
286 (IACUC) at Texas A&M University.

287 **Statistical Analyses.**

288 Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc, La Jolla, CA).
289 The statistical analysis used is listed in the figure legends. Significance was determined by p-values
290 equal to or less than 0.05.

291 **Results.**

292 **Construction of the *cyaB* and SR0623 mutant and complement strains.**

293 To investigate *B. burgdorferi cyaB*, we generated a deletion of *bb0723* by replacing the
294 ORF with the P_{flgB} -*aadA* antibiotic cassette in 5A4-NP1 (WT) resulting in strain JH522 (Figure 1
295 & Table 1) (Kawabata, Norris, and Watanabe 2004). The 3' end of *cyaB* overlaps with the 3' end
296 of its neighboring gene *bb0722* by 26 base pairs, which was not deleted in the *cyaB*⁻ strain. In
297 addition, the sRNA SR0623 is encoded within the 3' end of *cyaB* (95 base pairs) and with *bb0722*
298 (88 base pairs) (Popitsch et al. 2017). SR0623 could either be a result of RNA processing of the
299 *cyaB* mRNA or it could have its own promoter within *cyaB*. Adams et al. globally identified the 5'
300 end transcriptome and identified putative transcriptional start sites (TSSs) in *B. burgdorferi*
301 (Adams et al. 2017). A putative TSS was not identified within the *cyaB* ORF suggesting SR0623
302 is synthesized via *cyaB* mRNA processing. To distinguish the functional contribution of CyaB
303 from the sRNA SR0623, we made three chromosomal complements of *cyaB* using its native
304 promoter and P_{flgB} -*aacC1* antibiotic cassette but included different forms of SR0623 (Figure 1).
305 VA200 encodes *cyaB* and a truncated SR0623, designated *c-cyaB*. A *cyaB* and full length SR0623
306 is restored in VA272 and named *c-cyaB*-SR0623. A site-directed mutant of SR0623 was generated
307 by altering every third base-pair in the wobble position to disrupt the sRNA primary and secondary
308 structure while maintaining the amino acid sequence of CyaB in complement strain VA336,
309 referred to as *c-cyaB*-SR0623w. For independent verification of the *cyaB* phenotype, deletion and
310 complement strains were also generated in the ML23 background strain. The *cyaB*⁻ strain, JH441,
311 was chromosomally complemented with *cyaB* and SR0623, generating *c-cyaB*-SR0623 strain
312 JH446. JH441 and JH446 were transformed with pBBE22*luc* for in vivo imaging studies (Hyde et
313 al. 2011; Hyde and Skare 2018).

314 The absence of polar effects on the neighboring genes and confirmation of *cyaB* expression
315 in our strains was verified qualitatively by RT-PCR (Figure 2A). As expected, *cyaB* transcript was
316 detected in WT, *c-cyaB*, *c-cyaB*-SR0623, and *c-cyaB*-SR0623w with a notable absence in the
317 *cyaB*⁻ strain. Expression of *bb0722* and *bb0724* was observed in all strains. To evaluate the
318 expression of *cyaB* and SR0623 northern blots were performed with probes designed to hybridize
319 to the 5' end of SR0623 (Figure 2B). The *cyaB* transcript (484bp) and SR0623 (~158 bp) are
320 present in the WT strain and absent in the *cyaB*⁻ strains, as anticipated. *c-cyaB* produces a *cyaB*
321 transcript and lacks SR0623. *c-cyaB*-SR0623 expresses more *cyaB* and SR0623 than WT strain,
322 which may alter the levels of CyaB protein and perhaps the function of SR0623. *c-cyaB*-SR0623w
323 strain does not have a detectable *cyaB* or SR0623 because the engineered wobble-base mutations
324 prevent the probe from binding. Together, this data suggests that steady-state levels of the *cyaB*
325 mRNA are dependent on its 3' UTR, which also encodes SR0623.

326 ***cyaB* does not contribute to the oxidative stress response.**

327 *B. burgdorferi* is able to sense and combat oxidative stress by mechanisms that are not fully
328 understood (Boylan, Posey, and Gherardini 2003; Boylan et al. 2008; Seshu, Boylan, Hyde, et al.
329 2004; Boylan et al. 2006; Hyde et al. 2009; Ramsey et al. 2017). A Tn-seq screen by Ramsey et
330 al. found *B. burgdorferi* disrupted in *cyaB* had a two-fold decrease in fitness after exposure to
331 H₂O₂, therefore we sought out to determine if the AC contributed to the oxidative stress response
332 similar to other pathogens (Ramsey et al. 2017). *B. burgdorferi* strains, WT and *cyaB*⁻, were

333 exposed to increasing concentrations of H₂O₂, then serially diluted to determine the survival
334 percentage. We found that *cydB*⁻ strain survival was comparable to the WT strain 5A4-NP1 (Figure
335 3). There are several reasons our *cydB*⁻ phenotype does not correlate with Ramsey et al. *cydB* Tn-
336 seq phenotype. Ramsey et al. exposed a pool of transposon disruption mutants to an oxidative
337 stressor and measured fitness of the population whereas we are examining a single strain and its
338 survival. Another reason for the difference in findings may be the *B. burgdorferi* growth condition
339 prior to conducting the assay. We grew our cells to mid-log phase in BSK-lite lacking glucose and
340 supplemented with glycerol rather than complete BSKII. It was important for us to limit glucose
341 in the media because in some bacteria, such as *Vibrio cholerae* and *E. coli*, the presence of glucose
342 has been shown to alter AC activity and therefore cAMP production (Liang et al. 2007; Gstrein-
343 Reider and Schweiger 1982). Previous studies used BSK-glycerol to grow *B. burgdorferi* when
344 investigation of secondary metabolite c-di-GMP was evaluated (He et al. 2011). We found that
345 absence or addition of glycerol to the BSK-lite did not influence *B. burgdorferi* growth or alter
346 mammalian virulence factor production (Figure S2).

347 ***cydB* influences borrelial virulence determinants.**

348 Loss of an AC results in attenuation of virulence factors in many different bacteria, such
349 as *Pseudomonas aeruginosa* and *Salmonella typhimurium*, therefore we were interested in
350 examining the influence of *cydB* on important *B. burgdorferi* virulence determinants (R. S. Smith,
351 Wolfgang, and Lory 2004; Curtiss and Kelly 1987). Transcript levels were measured for multiple
352 *B. burgdorferi* targets that included genes important for regulation in the tick vector (*hkI*, *rrpI*,
353 *plzA*, and *ospA*) and mammalian virulence genes (*badR*, *bosR*, *rpoS*, *ospC*, *dbpA*, and *bbk32*)
354 (Figure 4). No changes were observed for genes shown to be operative in the arthropod-borne
355 phase of infection, which may be due to secondary messenger c-di-GMP being involved in the
356 vector (Figure 4A) (Rogers et al. 2009; He et al. 2014). Surprisingly, only *ospC* transcription was
357 found to be statistically significantly reduced 14-fold in the *cydB*⁻ strain compared to WT (Figure
358 4B). The expression of *ospC* was fully and partially restored to WT level in the *c-cydB*-SR0623w
359 and *c-cydB* strains, respectively. The *c-cydB*-SR0623 had an *ospC* transcript level similar to the
360 *cydB*⁻ strain. This transcriptional data indicates that *cydB* may be able to influence *B. burgdorferi*
361 mammalian virulence determinant expression.

362 cAMP plays an important role in post-transcriptional regulation in many bacteria, for
363 example, in *S. enterica* cAMP-CRP post-transcriptionally regulates transcriptional regulator Hild
364 resulting in reduced virulence factor production (Mouali et al. 2018). Our next step was to evaluate
365 the impact of *cydB* on the protein production of *B. burgdorferi* virulence determinants. We used
366 immunoblotting to examine the protein levels of several borrelial components associated with the
367 tick and mammalian pathways (Figure 5). Virulence determinants PlzA and OspA, important for
368 survival in the tick, and mammalian virulence determinants Rrp2 and BadR, were not altered in
369 the *cydB*⁻ strain compared to WT. *bosR* undergoes transcriptional and post-transcriptional
370 regulation in response to pH or metals and CO₂, respectively, by unknown mechanisms, therefore
371 we considered that BosR may also be post-transcriptionally regulated by cAMP (Hyde,
372 Trzeciakowski, and Skare 2007; Saputra, Trzeciakowski, and Hyde 2020). We found that the *cydB*⁻
373 strain produced less BosR relative to WT demonstrating another condition where BosR is post-
374 transcriptionally regulated given there was no difference observed in *bosR* expression (Figure 4 &
375 5). Strains *c-cydB* and *c-cydB*-SR0623w restored BosR protein production back to approximate
376 WT levels. However, the *c-cydB*-SR0623 complement had BosR protein levels comparable to the

377 *cyaB*⁻ strain. The lack of complementation of *c-cyaB*-SR0623 may be in part due to different
378 expression levels of *cyaB* and SR0623 observed by Northern analysis (Figure 2B). DbpA and
379 OspC protein production followed the same pattern as BosR. The different phenotypes of
380 complement *cyaB* strains suggests a possible regulation of *cyaB* by SR0623. Collectively, these
381 results would indicate that CyaB or cAMP, directly or indirectly, post-transcriptionally activates
382 both BosR and DbpA. This data confirms that the changes observed in the *ospC* transcript
383 influence the OspC protein level. It remains unclear if OspC and DbpA are being regulated by
384 *cyaB* independently or through BosR regulation of *rpoS*.

385 ***cyaB* expression is induced by host cell interaction.**

386 *B. burgdorferi* gene expression is highly responsive to changes in various environmental
387 cues and may also impact *cyaB* expression. Under BSK cultivation with shifts in temperature, pH,
388 and CO₂ we observed no significant changes in *cyaB* transcript (data not shown). To investigate if
389 expression of *cyaB* is influenced by tick or mammalian cellular factors, we co-cultured *B.*
390 *burgdorferi* strain 5A4-NP1 for 24 hours with the tick neuroglial cell line ISE6 or the mammalian
391 neuroglial cell line H4 and harvested bacteria in the cell culture media (Figure 6) (Livengood,
392 Schmit, and Gilmore 2008; Oliver et al. 1993). *cyaB* expression was not significantly changed at
393 the time points tested in the tick neuroglial cell line ISE6 relative to *B. burgdorferi* incubated in
394 cell culture media alone. Mammalian neuroglial cell line H4 significantly induced the borrelial
395 *cyaB* expression after 24-hour co-incubation. These results indicate that *cyaB* expression is
396 influenced by cellular factor(s) unique to mammalian cell lines and not by in vitro grown tick cells
397 or during in vitro cultivation in BSKII media.

398 **The absence *cyaB* results in attenuated infection.**

399 Given that deletion of *cyaB* resulted in altered mammalian virulence determinants, we
400 hypothesized that infecting mice with the *cyaB*⁻ strain would alter infectivity. C3H/HeN mice were
401 intradermally infected with the WT, *cyaB*⁻ strain, or complement strains. Tissues were collected at
402 7, 14, and 21 days post-infection (dpi) for both qualitative outgrowth and quantitative molecular
403 analysis of infection. Cultivation data shows that all harvested tissues from mice infected with the
404 WT strain were positive for *B. burgdorferi* by day 14, whereas, half the tissues for the *cyaB*⁻ strain
405 did not have bacterial outgrowth (Table 2). Unfortunately, none of the three complement strains
406 were able to restore infectivity to WT levels. This was surprising given that the qRT-PCR,
407 Northern, and Western data show that the *c-cyaB* and *c-cyaB*-SR0623w strains restore the *cyaB* in
408 vitro deletion phenotypes. *B. burgdorferi* burden of individual infected tissues was analyzed by
409 qPCR to determine the bacterial burden. The *cyaB*⁻ strain was significantly lower at 7 dpi in lymph
410 nodes, bladders, and skin flanks adjacent to the inoculum site. The ears, a distal skin colonization,
411 and joints had less *B. burgdorferi* at 14 and 21dpi, respectively, when infected with the *cyaB*⁻ strain
412 (Figure 7). The *cyaB* complements had borrelial loads similar to the *cyaB*⁻ strain. Taken together
413 this data would indicate that *cyaB* plays a role in mammalian infectivity.

414 To independently evaluate the influence of *cyaB* on infectivity, we generated a *cyaB*
415 deletion in the ML23 background that is used to track bioluminescent imaging during murine
416 infection as a way to evaluate temporal and spatial dissemination (Hyde et al. 2011, 32; Hyde and
417 Skare 2018). The parent (ML23), *cyaB*⁻ (JH441), and *c-cyaB*-SR0623 complement (JH446) strains
418 had pBBE22*luc* introduced into them were tested for disseminated infectivity using light emission

419 as a reporter for live *B. burgdorferi* (Hyde et al. 2011). Western analysis of the aforementioned
420 showed less protein production of BosR, DbpA, and OspC in the *cyaB*⁻ strain as was observed in
421 the 5A4-NP1 background mutant (Figure S3). Balb/c mice were then infected with the *B.*
422 *burgdorferi* strains and in vivo imaged at 0, 1, 4, 7, 10, 14, and 21 dpi. The bioluminescent tracking
423 shows the bacteria being localized to the site of injection early at day 0 and then progressing to
424 distal tissues throughout the mouse by day 21 (Figure 8A). At 7 dpi, the peak of infection, the
425 parent strain produces three times more light than the *cyaB*⁻ strain; however, the *c-cyaB*-SR0623
426 complement strain is not able to restore the light emission observed for the parent strain (Figure
427 8B). The parent strain disseminates to distal tissues through day 21. This dissemination is not
428 observed in the *cyaB*⁻ or *c-cyaB*-SR0623 strains, which instead stay localized near the site of
429 injection. After imaging on day 21, mice tissues, lymph nodes, skin flanks, ears, and joints, were
430 harvested and used for cultivation. We found a slight reduction in the number of infected tissues
431 in *cyaB*⁻ strain and *c-cyaB*-SR0623 *B. burgdorferi* (Figure 8C). It is interesting to note that the ears
432 of the *cyaB*⁻ strain and *c-cyaB*-SR0623 strain infected mice were negative for *B. burgdorferi*,
433 suggesting the genetic modifications may alter tissue dissemination. This independently validates
434 the infectivity data in the 5A4-NP1 background and, taken together, despite the issues with
435 incomplete complementation, supports the finding that *cyaB* is important for murine infection.

436 Discussion.

437 *B. burgdorferi* gene regulation is dynamic and highly responsive to changes in
438 environmental conditions to support the necessary adaptation for traversing between the tick vector
439 and mammalian host (Radolf et al. 2012; D. Scott Samuels and Samuels 2016). The mechanisms
440 used by *B. burgdorferi* to directly sense environmental conditions and relay that information to
441 alter gene regulation are poorly understood. We hypothesize that *B. burgdorferi* uses an AC (*cyaB*,
442 *bb0723*) and possibly cAMP for the response to environmental cues and to regulate virulence
443 determinants important for mammalian infection. ACs cyclize ATP producing cAMP which
444 functions as a secondary messenger in eukaryotes and prokaryotes (Stanley McKnight 1991;
445 Botsford and Harman 1992; Kamenetsky et al. 2006; McDonough and Rodriguez 2011). In
446 bacteria, ACs and/or cAMP are responsive to a variety of environmental changes, such as carbon
447 starvation, CO₂ levels, bicarbonate, osmolarity, and pH (Hoffmaster and Koehler 1997; Franchini,
448 Ihssen, and Egli 2015; Cann et al. 2003; Rebollo-Ramirez and Larrouy-Maumus 2019). cAMP is
449 used by numerous bacterial pathogens to alter both the host and pathogen at the level of post-
450 transcriptional regulation for signal reception, signal transduction, AC activity, virulence gene
451 regulation, resistance to oxidative stress, and persistence (Molina-Quiroz et al. 2018). It is well
452 documented that *B. burgdorferi* utilizes cyclic dinucleotides during the tick and mammalian stages
453 of pathogenesis to modulate the necessary gene regulation for response to environmental pressures,
454 therefore it is plausible it also relies on cyclic nucleotides for regulation (Savage et al. 2015; Ye et
455 al. 2014; Melissa J. Caimano et al. 2015; He et al. 2011; Zhang et al. 2018; Rogers et al. 2009). It
456 is important to understand the strategies employed by *B. burgdorferi* to adapt to changing
457 environmental conditions to evaluate borrelial pathogenesis in the context of mammalian infection.

458 In this study, a genetic approach was used to evaluate the borrelial *cyaB* contribution to the
459 regulation of virulence determinants and mammalian infectivity. Borrelial *cyaB* has been
460 annotated as a class IV AC, which is the smallest of the classes and has been previously crystalized
461 in *Yersinia pestis* (Casjens et al. 2000; Khajanchi et al. 2016). *cyaB* is encoded on the positive
462 strand and overlaps with *bb0722* encoded on the opposite strand. Deletion mutants of *cyaB* in two
463 independent *B. burgdorferi* strains, 5A4-NP1 and ML23, were generated that also disrupted
464 SR0623. Three unique complement strains, *cyaB* only, *cyaB* with SR0623, and *cyaB* with a
465 mutagenized SR0623, were generated to clarify the contribution of *cyaB*, SR0623, and the
466 combination of *cyaB* and SR0623 to our readouts of borrelial infectivity (Figure 1). The complete
467 deletion of the *cyaB* ORF also truncates SR0623 and results in a reduction in the production of
468 important mammalian virulence determinants BosR, OspC, and DbpA, while tick virulence
469 determinants are unchanged (Figure 5). Interestingly, only *ospC* was transcriptionally down
470 regulated in the *cyaB* deletion strains (Figure 4). Complement strains encoding the *cyaB* ORF with
471 a truncated or mutagenized SR0623 were able to restore protein production to WT levels,
472 suggesting the sRNA is not necessary for regulation of OspC, BosR or DbpA. Unexpectedly, the
473 complement with *cyaB* and a complete SR0623 produced only slightly higher levels of BosR,
474 OspC, and DbpA than the mutant. Northern analysis demonstrated higher levels of *cyaB* transcript
475 and SR0623 in the *cyaB*-SR0623 complement strain relative to WT, which may explain the partial
476 complementation phenotype (Figure 2). This data demonstrates *cyaB* contributes to transcriptional
477 and post-transcriptional regulation of selected *B. burgdorferi* genes. Furthermore, *cyaB*, and
478 possibly cAMP, are involved in regulation of factors specific for borrelial pathogenicity.

479 *B. burgdorferi* is greatly influenced by environmental conditions and may use *cyaB* as an
480 environmental sensor (Radolf et al. 2012; D. Scott Samuels and Samuels 2016). We examined the
481 *cyaB* mutant and complement strains under a variety of growth conditions by imposing oxidative
482 stress, as well as shifting temperature, pH, and CO₂, and found no phenotypic differences (Figure
483 3 & data not shown). Knowing that different carbon sources can alter cyclase activity and
484 production of cyclic nucleotide and di-nucleotides media that replaced glucose with glycerol was
485 used to examine regulation of borrelial virulence factors (Liu et al. 2020; Peterkofsky and Gazdar
486 1974). Differences in borrelial virulence determinant protein production were more pronounced in
487 BSK-lite, independent of glycerol supplementation, relative to conventional BSKII (Figure S2 &
488 data not shown). Further investigation indicated BSK-lite with or without glycerol resulted in the
489 same pattern of protein production signifying glucose as the carbon source was responsible for the
490 differential response and demonstrating borrelial catabolite repression.

491 *B. burgdorferi* is highly responsive to host specific signals and it is possible *cyaB* is
492 involved in signaling for mammalian adaptation. We evaluated *cyaB* expression when co-cultured
493 with vector or mammalian cells to mimic interactions during the pathogenic cycle. The expression
494 of *cyaB* is induced when co-cultured with mammalian H4 neuroglial cells, but unchanged with
495 tick ISE6 cells (Figure 6). Due to *cyaB* induced expression in the presence of mammalian cells,
496 we also evaluated the contribution of *cyaB* to mammalian infection. During mouse infection the
497 *cyaB* mutant strains had lower borrelial colonization, particularly during early time points (Figure
498 7 & 8). In later infection disseminated tissues, notably the ear and tibiotarsal joint, also had lower
499 *B. burgdorferi* load relative to the infectious parent strain. Unfortunately, the complement strains
500 that restored virulence determinant production in vitro did not colonize tissues at the same level as
501 parental *B. burgdorferi*. The data is strengthened by similar results in two independent borrelial
502 strains. Infectivity studies demonstrated that the absence of *cyaB* results in inhibited dissemination
503 and attenuated infection. Together, this suggests *cyaB* contributes to mammalian colonization and
504 supports this stage of the life cycle.

505 Khajanchi et al. evaluated the functional ability of *cyaB* and contribution to mouse
506 infection using the *cyaB* transposon mutants (Khajanchi et al. 2016). This study showed
507 recombinant CyaB produced cAMP in a temperature dependent manner but was not evaluated
508 directly in *B. burgdorferi*. Our attempts to measure cAMP production during cultivation of *B.*
509 *burgdorferi* have been unsuccessful likely due to the low-level expression and production of *cyaB*
510 under these conditions. Transposon mutants with insertions in *cyaB* (insertion ratios 0.02 and 0.93)
511 did not demonstrate an infectivity phenotype by needle inoculation or tick transmission (Khajanchi
512 et al. 2016). Infectivity was qualitatively evaluated by borrelial outgrowth from infected tissues
513 following a 28-day infection in which all tissues were positive for the presence of the bacteria. Our
514 findings observed *B. burgdorferi* in most tissues at the last time point with the exception of the
515 ears that was not assessed in the prior work. We quantitated the borrelial load of the whole mouse
516 and individual tissues by bioluminescent imaging and qPCR, respectively. We found that overall
517 borrelial load was reduced that were specifically lower in the skin flank and bladders during early
518 infection, but remained low in the ear and the tibiotarsal joints. We have also investigated the
519 involvement of SR0623 that was unknown at the time of previous studies. This indicates that *cyaB*
520 may contribute to pathogenesis during earlier borrelial infection that can be overcome by
521 compensatory, but unknown genes, to be able to reach a fully disseminated infection. Our study
522 further pursued the role of borrelial ACs by investigating the regulatory effect of *cyaB* on known
523 borrelial virulence determinants. While this study focused on a few targets it is likely that *cyaB*

524 and cAMP have a broader impact on transcriptional and post-transcriptional regulation in *B.*
525 *burgdorferi*.

526 Another important aspect of bacterial post-transcriptional regulation is the contribution by
527 sRNAs. Over a thousand sRNAs were recently identified in *B. burgdorferi* (Popitsch et al. 2017),
528 but few have been characterize. SR0623 is an intragenic sRNA that is encoded on the negative
529 strand within the 3' end of *cyaB* (*bb0723*) and overlaps with the hypothetical gene *bb0722* (Figure
530 1). SR0623 is predicted to be transcribed with *cyaB* and processed, which could result in a
531 truncated *cyaB* transcript. Intragenic sRNAs in other bacteria regulate the genes they are encoded
532 within, therefore SR0623 may regulate *cyaB* and/or *bb0722*. In addition, intragenic RNAs have
533 been co-immunoprecipitated with RNA binding proteins and other mRNAs and sRNAs, indicating
534 they may have multiple targets beside the genes they are encoded within (Melamed et al. 2020;
535 Iosub et al. 2020; Melamed et al. 2016; Bilusic et al. 2014). In the complement with truncated
536 SR0623 there is lower steady-state levels of *cyaB* compared to the WT, indicating SR0623 and/or
537 the 3' end of the *cyaB* transcript are important for regulating *cyaB* steady-state transcript levels.
538 Furthermore, in the *cyaB* full-length SR0623 compliment there is higher steady state levels of *cyaB*
539 and SR0623. Interestingly, both ACs and sRNAs function in post-transcriptional regulation.
540 Finally, we also cannot rule out that our observed phenotype and challenges with complementation
541 may be in part attributed to SR0623 regulation of *bb0722* or the intra RNA SR0622 encoded with
542 in it.

543 The current study does not address the direct detection of cAMP from cultivated *B.*
544 *burgdorferi*. Future studies will investigate the environmental conditions in vitro and in vivo that
545 promotes the production of cAMP and determine if it correlates with expression or production of
546 *cyaB*. Here in, we narrowly focused on the regulation of known tick and mammalian virulence
547 determinant, but it is likely that *cyaB* and cAMP have a broader post-transcription regulatory
548 impact on *B. burgdorferi*. The various strategies used to complement *cyaB* and/or SR0623 resulted
549 in restoration phenotypes under in vitro conditions, but unfortunately were not able to completely
550 restore the WT phenotype during mouse infection. This could be due to altered processing or
551 stability of SR0623 and/or *cyaB* in the complement strains, which may impact the AC activity
552 specifically induced under host adapted conditions. Our study is not the first to have difficulty
553 complementing a borrelial gene or sRNA and represents a broader challenge in the field of
554 bacterial pathogenesis. Further study is required to distinguish the function of intergenic sRNA
555 from the gene it is encoded within to fully understand the complex regulation of *B. burgdorferi*.

556 In this study, we identified the ability of *cyaB* to contribute to the regulation of mammalian
557 virulence determinants and infectivity in mice. This phenotype is presumably due to the production
558 of cAMP and its impact on post-transcriptional regulation in *B. burgdorferi*. It also shed light on
559 the complexities and possible contribution of sRNA to borrelial regulation in which the distinct
560 responses are observed under cultivation conditions and/or during infection. It has become clear
561 that *B. burgdorferi* utilizes post-transcriptional regulation to support pathogenesis and to provide
562 a dynamic means to adapt to the various milieus that Lyme spirochetes move between during its
563 complex lifecycle.

564 **Figure legends.**

565 **Figure 1. Schematic of the *cyaB* mutant and *trans*-complement strains.** The *cyaB* deletion
566 strain JH522 was generated through the insertion of an *aadA* antibiotic cassette to disrupt *cyaB*
567 (*bb0723*) while keeping *bb0722* intact. Chromosomal *cyaB* complementation strains were made
568 through the introduction of an *aacCI* antibiotic cassette. Complement strain VA200 contains the
569 *cyaB* ORF while truncating the sRNA SR0623, strain VA272 contains both the *cyaB* ORF and
570 SR0623, and strain VA336 contains the *cyaB* ORF and a wobble mutation of SR0623. ORFs are
571 indicated by arrows and sRNAs by wavy lines.

572 **Figure 2. Verification of strains generated in this study.** (A) Deletion of *cyaB* does not abolish
573 transcription of neighboring genes *bb0722* or *bb0724*. RT-PCR was used to verify the presence or
574 absence of transcripts in the indicated *B. burgdorferi* strains. RNA was isolated and used to
575 generate cDNA as describe in the methods. The +/- symbols indicates if the cDNA reaction with
576 or without reverse transcriptase. PCR reactions included cDNA and primers for *cyaB* (*bb0723*),
577 *bb0722*, or *bb0724*. (B) sRNA-sequencing results are displayed in the coverage map (Popitsch et
578 al. 2017). The + strand is shown in green and the – strand in blue. Northern blot analyses of total
579 RNA fractionated on a 6% denaturing polyacrylamide gel, blotted to a nylon membrane and
580 hybridized with radioactive oligonucleotides. The black line represents the location of the
581 oligonucleotide probes. The genomic context is indicated below the coverage plot. The predicted
582 transcripts are denoted and marked with the appropriate band in the Northern blot. Northern blots
583 are representative of three biological replicates. The following abbreviations are used to indicate
584 strains: WT (P), *cyaB*⁻ (M), *c-cyaB* (C), *c-cyaB*-SR0623 (S), *c-cyaB*-SR0623w (W).

585 **Figure 3. *cyaB* does not contribute to H₂O₂ resistance.** WT and *cyaB*⁻ strains were grown in
586 BSK-glycerol to mid-log phase at 32°C 1% CO₂, exposed to H₂O₂ in modified BSK media for 4
587 hours at 32°C 1% CO₂, and serial diluted for outgrowth to determine survival. Shown is the
588 average and standard error of three independent biological replicates.

589 **Figure 4. Deletion of *cyaB* reduces *ospC* expression.** *B. burgdorferi* was grown in BSK-glycerol
590 to mid-logarithmic phase at 32°C 1% CO₂ for qRT-PCR analysis to investigate the relative
591 transcript levels of virulence determinants for the (A) tick and (B) mammalian cycle. *flaB* was
592 used as an endogenous control and fold changes are compared to WT. Shown are the averages and
593 standard error of three biological replicates. Statistical analysis was performed using one-way
594 ANOVA with Dunnett correction relative to WT, *** p<0.001.

595 **Figure 5. Deletion of *cyaB* reduces protein production of BosR, OspC, and DbpA.** *B.*
596 *burgdorferi* was grown in BSK-glycerol to mid-logarithmic phase at 32°C 1% CO₂. Protein was
597 harvested and resolved on a SDS-PAGE with approximately 4x10⁷ *B. burgdorferi* in each lane.
598 Immunoblots were prepared using the depicted anti-serum. FlaB was used as a loading control.
599 Displayed is representative of three independent replicates. The following abbreviations are used
600 to indicate strains: WT (P), *cyaB*⁻ (M), *c-cyaB* (C), *c-cyaB*-SR0623 (S), *c-cyaB*-SR0623w (W).

601 **Figure 6. *cyaB* expression is induced with mammalian H4 cell co-culture.** *B. burgdorferi* was
602 co-cultured with ISE6 tick cells or H4 mammalian cells. qRT-PCR was performed on samples
603 collected at 3, 6, and 24 hours co-incubation. *flaB* was used as an endogenous control. Shown is

604 the average and standard error of four biological replicates. Statistical analysis was done using
605 Two-way ANOVA with Tukey correction, *p-value<0.05.

606 **Figure 7. Borrelial burden and tissue dissemination is reduced in mouse tissues infected with**
607 **the *cyaB* mutant.** C3H/HeN mice were infected with 10^5 *B. burgdorferi* and tissues were
608 harvested at 7, 14, and 21 dpi. qPCR was performed on (A) Ears, (B) Skin Flanks, (C) Joints, and
609 (D) Bladders to determine the number of borrelial genomes (*recA*) per 10^6 copies of mouse β -actin.
610 Individual data points with at least n of 4 with lines representing average and standard error.
611 Statistical analysis was done using Two-way ANOVA with Dunnett correction relative to WT,
612 **p-value<0.01, ***p-value<0.001, ****p-value<0.0001.

613 **Figure 8. Bioluminescent *cyaB*⁻ has attenuated infection and dissemination.** (A)
614 Bioluminescent *B. burgdorferi* is temporal and spatial tracked during infection of Balb/c mice with
615 10^5 WT, *cyaB*⁻, or *c-cyaB*-SR0623. Mice were imaged at 1 hour and 1, 4, 7, 10, 14 and 21 dpi. The
616 mouse in the first position of the image, indicated by (-), did not receive D-luciferin to serve as a
617 background control. n of 5 for each infection group. (B) The bioluminescence of four mice was
618 quantitated and averaged. Statistical analysis was performed using Two-way ANOVA with Tukey
619 correction relative to WT, ****p-value<0.0001. (C) The percentage of tissues positive for *B.*
620 *burgdorferi* at 21 dpi, grown in BSKII+NRS.

621 **Supplemental Figure 1. SR0623 wobble mutation sequence.** Site directed mutagenesis of every
622 third base pair of the sRNA SR0623 sequence is denoted by underlining. The *cyaB* ORF stop
623 codon is indicated by an asterisk. The stop codon for the overlapping *bb0722* ORF is outlined by
624 a box. The numbers indicate the distance from the *cyaB* ORF start codon.

625 **Supplemental Figure 2. Glycerol does not alter *B. burgdorferi* virulence factor production.**
626 The *B. burgdorferi* strains 5A4-NP1 (WT) and JH522 (*cyaB*⁻) were grown in BSK-lite with or
627 without 0.6% glycerol to mid-logarithmic phase at 32°C 1% CO₂. Protein was harvested and
628 resolved on a SDS-PAGE with each lane containing approximately 4×10^7 *B. burgdorferi*.
629 Immunoblotting was carried out using the anti-serum depicted. FlaB was used as a loading control.
630 Representative of at least three independent replicates.

631 **Supplemental Figure 3. Mammalian virulence factors production in bioluminescent *cyaB***
632 **mutant.** *B. burgdorferi* ML23 strains were grown in BSK-glycerol to mid-log phase at 32°C 1%
633 CO₂. Protein was harvested and resolved on a SDS-PAGE with each lane containing
634 approximately 4×10^7 *B. burgdorferi*. Immunoblots were probed using the anti-serum depicted.
635 FlaB was used as a loading control. Representative of at least three individual replicates. The
636 following abbreviations are used to indicate strains: ML23 pBBE22*luc* (P), JH441 pBBE22*luc*
637 (M), JH446 pBBE22*luc* (C).

638 **Table 1.** Strains and plasmids used in this study.

Strain	Genotype	Reference
<i>B. burgdorferi</i> strains		
5A4-NP1	Clonal infectious isolate of 5A4 with <i>bbe02</i> disrupted with P_{flgB} - <i>kan</i> , lacking <i>cp9</i>	(Kawabata, Norris, and Watanabe 2004)
JH522	5A4-NP1 <i>bb0723</i> :: Sm^R	This study
VA200	JH522 $P_{cyaB512}$ -FLAG- <i>cyaB</i> :: $Gent^R$	This study
VA272	JH522 $P_{cyaB512}$ -FLAG- <i>cyaB</i> -SR0623:: $Gent^R$	This study
VA336	JH522 $P_{cyaB512}$ -FLAG- <i>cyaB</i> -SR0623wobble:: $Gent^R$	This study
JH522 pVA102	JH522 carrying pVA87:: P_{pQE30} -FLAG- <i>cyaB</i> , $Gent^R$	This study
ML23	Clonal isolate of strain B31 lacking <i>lp25</i> and <i>cp9</i>	(Labandeira-Rey and Skare 2001)
JH441 pBBE22 <i>luc</i>	ML23 <i>bb0723</i> :: Sm^R carrying constitutive bioluminescence shuttle vector	This study
JH446 pBBE22 <i>luc</i>	JH441 $P_{cyaB336}$ - <i>cyaB</i> -SR0623:: $Gent^R$ carrying constitutive bioluminescence shuttle vector	This study
<i>E. coli</i> strains		
NEB 10 β	<i>araD139</i> Δ (<i>ara, leu</i>)7697 <i>fhuA lacX74 galK16 galE15 mcrA</i> ϕ 80d(<i>lacZ</i> Δ M15) <i>recA1 relA1 endA1 nupG rpsL rph spoT1</i> Δ (<i>mrrhsdRMS-mcrBC</i>)	New England Biolabs
Plasmids		
pCR8	Intermediate for TOPO cloning, $Spec^R$	ThermoFisher
pENTR1a-N3xFLAG	Kan^R	ThermoFisher
pJH333	Allelic exchange vector, $Spec^R$ and $Gent^R$	This study
pVA110	Allelic exchange vector, $Spec^R$ and $Gent^R$	This study
pBSV2G	Shuttle vector, $Gent^R$	(Elias et al. 2003)
pJSB268	pKFSS1:: P_{pQE30} - <i>luc</i> + P_{flaB} - <i>lacI</i> , $Spec^R$	(J. S. Blevins et al. 2007)
pJH380	pCR8 encoding 1.5kb <i>cyaB</i> upstream region	This study
pJH381	pCR8 encoding 1.5kb <i>cyaB</i> downstream region	This study
pJH383	pCR8 <i>cyaB</i> upstream and downstream regions	This study
pJH431	pCR2.1:: P_{flgB} - <i>aadA</i>	This study
pJH432	<i>cyaB</i> deletion construct, $Spec^R$	This study
pJH446	pJH333:: <i>cyaB</i> , $Spec^R$	This study
pVA85	pENTR1a-N3xFLAG:: <i>cyaB</i> -SR0623, Kan^R	This study
pVA87	pJSB268 with <i>Gent</i> cassette, $Gent^R$	This study
pVA102	pVA87:: P_{pQE30} -FLAG- <i>cyaB</i> , $Gent^R$	This study

pVA112	pVA110::P _{cyaB} 512-FLAG- <i>cyaB</i> , Gent ^R	This study
pVA114	pVA110::P _{cyaB} 512-FLAG- <i>cyaB</i> -SR0623, Gent ^R	This study
pVA146	pVA110::P _{cyaB} 512- <i>cyaB</i> -SR0623wobble, Gent ^R	This study
pBBE22 <i>luc</i>	Shuttle luminescent vector P _{flaB} - <i>Bbluc</i> , Kan ^R	(Hyde et al. 2011)
pCR2.1::βactin	pCR2.1 carrying murine β-actin, Kan ^R	(Maruskova et al. 2008)
pCR2.1:: <i>recA</i>	pCR2.1 carrying <i>B. burgdorferi recA</i> Kan ^R	(Wu et al. 2011)

639

640 **Table 2.** Tissue infectivity of *B. burgdorferi* infected mice.

Day 7		number of positive cultures/total			
strain	lymph node	skin flank	ear	all sites	% positive all sites
WT	5/5	5/5	1/5	11/15	73
<i>cyaB</i> ⁻	0/5	1/5	0/5	1/15	6
<i>c-cyaB</i>	0/5	0/5	0/5	0/15	0
<i>c-cyaB</i> -SR0623	1/5	1/5	0/5	2/15	13
<i>c-cyaB</i> -SR0623w	2/5	4/5	0/5	6/15	40

Day 14		number of positive cultures/total			
strain	lymph node	skin flank	ear	all sites	% positive all sites
WT	4/4	4/4	4/4	12/12	100
<i>cyaB</i> ⁻	3/5	2/5	0/5	5/15	33
<i>c-cyaB</i>	0/5	0/5	0/5	0/20	0
<i>c-cyaB</i> -SR0623	2/5	2/5	0/5	4/15	26
<i>c-cyaB</i> -SR0623w	1/5	1/5	1/5	3/15	20

Day 21		number of positive cultures/total			
strain	lymph node	skin flank	ear	all sites	% positive all sites
WT	5/5	5/5	5/5	15/15	100
<i>cyaB</i> ⁻	2/5	2/5	0/5	4/15	26
<i>c-cyaB</i>	1/5	1/5	0/5	2/15	13
<i>c-cyaB</i> -SR0623	3/5	3/5	0/5	6/15	40
<i>c-cyaB</i> -SR0623w	3/5	3/5	1/5	7/15	46

641

642 **Supplemental Table 1.** Primers used in this study.

Primer Name	Sequence (5' to 3')	Purpose
<i>cyaB</i> US F	CAACTCAACTTTACAGAGTCTGTTC	Cloning
<i>cyaB</i> US R BamHI KpnI	ACGCGGATCCACGCGGTACCCTGAATTACTTTCAT TGGCAAATCAAAG	Cloning
<i>cyaB</i> DS F KpnI SphI	ACGCGGTACCACGCGCATGCATATTAATAAATAATG TAATTATG	Cloning
<i>cyaB</i> DS F BamHI	ACGCGGATCCGTGAATGCCTAAATTACTAAGTC	Cloning
PflgBF-SphI	ACGCGGTACCCTAATACCCGAGCTTCAAGG	Cloning
<i>aadAR</i> -KpnI	GCGTGCATGCCAGATCCGGATATAGTTCCTCC	Cloning
<i>cyaB</i> FLAG-F-NotI	ACGCGCGGCCGCCCTTTGAAATAGAATCAAAGC	Cloning
<i>cyaB</i> FLAG-R-XhoI	ACGCCTCGAGGTGCTGACATTGGGCTTTAT	Cloning
BbgenupF BamHI	GGATCCTATGCCTATGCAAAAAGCAG	Cloning
BbgenupR HpaI ClaI	GTAAACATCGATCAAAAAGCAGCTTGCAAATA	Cloning
BbgendownF HpaI ClaI	GTAAACATCGATTATGGCAGAGCTTGCAATTAT	Cloning
BbgendownR KpnI	GGTACCGCAAGTGAAAACCTCAAACCTTG	Cloning
pFlggentF-HpaIMCS	GTAAACGACGTCGACTGCAGTACTGAACGAATT	Cloning
PFlggentRHpaINotI	GTAAACGCGGCCCGAGCTTCAAGGAAGA	Cloning
<i>bb0445</i> -F-BamHI	ACGCGGATCCATGTTTGGTTTTGATTTAATAA	Cloning
<i>bb0445</i> -R	ACGCGGATCCATGTTTGGTTTTGATTTAATAA	Cloning
PflgB-F-NotI	ACGCGCGGCCGCTAACGACGTCGACTGCAGTA TACCCGAGCTTCAAGGAAGATTTCCATTAAAG	Cloning
gent-R	CTGCTTTTTGTTAGGTGGCGGTA CT TGGGT	Cloning
PcyaB-F-SalI	ACGCGTCGACATTA AACCTATCATTTC AATTG	Cloning
PcyaB-R	TGTAGTCCATATATTAATAAATAATGTAATTATGAT	Cloning
<i>cyaB</i> BORF-F	TTTTTAATATATGGACTACAAGGACCACGACGGCG	Cloning
<i>cyaB</i> BORF-R-SalI	ACGCGTCGACTTATTTTTTACTTTGATTG	Cloning
<i>cyaB</i> SR0623-R-SalI	ACGCGTCGACGTGCTGACATTGGGCTTTAT	Cloning
pJH446-F PstI	ACGCCTGCAGCCCAAGCTGGATTAGCAAC	Cloning
pJH446-R PstI	ACGCCTGCAGTGAGGACAATAATAATGTGAG	Cloning
PflgB-F-SalI	ACGCGTCGACTACCCGAGCTTCAAGGAAGA	Cloning
PflgB-R	GTAACATATAGAAACCTCCCTCATTTAAAAT	Cloning
GentR-F	GGGAGGTTTCTATATGTTACGCAGCAGCAAC	Cloning
GentR-R-AatII	ACGCGACGTCTTAGGTGGCGGTA CT TGGGT	Cloning
<i>cyaB</i> FLAG-F-NdeI	ACGCCATATGATGGACTACAAGGACCACGA	Cloning
<i>cyaB</i> FLAG-R-HindIII	ACGCAAGCTTTTATTTTTTACTTTGATTGCC	Cloning
<i>bb0722</i> RT F	GTAGCGATTCCCTGAAAGC	RT-PCR
<i>bb0722</i> RT R	CCTTCCATTTCAACATTAGGAC	RT-PCR
<i>bb0723</i> RT F	GTTTGAATAGAATCAAAGC	RT-PCR
<i>bb0723</i> RT R	CAGAGTAAGGTCTAGTTTC	RT-PCR
<i>bb0724</i> RT F	CCTGAAGCTATAGTTGTGG	RT-PCR

<i>bb0724</i> RT R	CCTTCCAATTGCCAGATCC	RT-PCR
<i>cyaB</i> F	AGACAACAACAATACTGTAGAAA	qRT-PCR
<i>cyaB</i> R	TTATTTCGTTTATCTCTACATTTA	qRT-PCR
<i>flaB</i> F	CAGCTAATGTTGCAAATCTTTTCTCT	qRT-PCR
<i>flaB</i> R	TTCCTGTTGAACACCCTCTTGA	qRT-PCR
<i>bosR</i> F	ACCCTATTCAACTTGACGATATTAAGAT	qRT-PCR
<i>bosR</i> R	GCCCTGAGTAAATGATTTCAATAGATT	qRT-PCR
<i>dbpA</i> F	CAGATGCAGCTGAAGAGAATCCT	qRT-PCR
<i>dbpA</i> R	ACCCTTTGTAATTTTCTCTCATTTTT	qRT-PCR
<i>badR</i> F	ACGCACTGCTGAACTTTCGATTTGGT	qRT-PCR
<i>badR</i> R	ACGCAGCATATTGACACAACCCTT	qRT-PCR
<i>plzA</i> F	ACGCGGATGTCGAGGAAGATGCAA	qRT-PCR
<i>plzA</i> R	ACGCAAAGCAATACCAAGCGCAA	qRT-PCR
<i>rpoS</i> F	ACGCATGCAAACCTTGCGACTTGTT	qRT-PCR
<i>rpoS</i> R	ACGCATCCCAAGTTGCCTTCTTGA	qRT-PCR
<i>ospC</i> F	CGGATTCTAATGCGGTTTTACTTG	qRT-PCR
<i>ospC</i> R	CAATAGCTTTAGCAGCAATTCATCT	qRT-PCR
<i>rrp1</i> F	AAGGTGCTTACGAGATTGAG	qRT-PCR
<i>rrp1</i> R	TCTGTGGAACTTCTTGAACATA	qRT-PCR
<i>hkl</i> F	CGTCAATTTATTTTCTAAGGATATTTTC	qRT-PCR
<i>hkl</i> R	TGCTTCGTCTTCAATTCACT	qRT-PCR
<i>ospA</i> F	GCAACAGTAGACAAGCTTGAGC	qRT-PCR
<i>ospA</i> R	GTGTGGTTTGACCTAGATCGTCA	qRT-PCR
<i>bbk32</i> F	GAATATAAAGGGATGACTCAAGGAAGTT	qRT-PCR
<i>bbk32</i> R	TTTGGCCTTAAATCAGAATCTATAGTAAGA	qRT-PCR
<i>recAB</i> F	GTGGATCTATTGTATTAGATGAGGCT	qRT-PCR
<i>recAB</i> R	GCCAAAGTTCTGCAACATTAACACCT	qRT-PCR
Bactin F	ACGCAGAGGGAAATCGTGCGTGAC	qRT-PCR
Bactin R	ACGCGGGAGGAAGAGGATGCGGCAG	qRT-PCR
SR0623 5' probe	GCCAATGAAAGTAATTCAGAGTAAGGTCTAGTTTC AATG	Northern
SR0623 3' probe	GCCCTCAGATTGGAATTTATGGCAATCAAGGGCTT GTAATCTCTAC	Northern

644 **Acknowledgements.**

645 Thank you to Dr. Jon Skare for the BosR antibody, Dr. Magnus Hook for the DbpA antibody, Dr.
646 Richard Marconi for the Rrp2 and OspC antibodies, Dr. Seshu Janakiram for the BadR antibody,
647 and Dr. Jenifer Coburn for P66 antibody. Appreciation to Dr. Rajesh Miranda for use of his ViiA7
648 Real-Time PCR machine (Applied Biosystems). We thank Dr. Ulrike Munderloh for providing
649 ISE6 cells. We also thank Dr. Jon Skare for thoughtful comments in the editing of this manuscript.

650 **Funding.**

651 Our funding was provided by the NIH R03 grant number AI103627-01A1.

652 **Conflict of interest statement.**

653 None of the authors have a financial conflict of interest.

654 **Author contributions.**

655 VA and JH were involved in the experimental design, data analysis and interpretation, and wrote
656 manuscript; VA executed a majority of the experiments; LV mammalian tissue culture
657 experiments; ES generated constructs and strains; AH & ML northern blots; ML consultation,
658 experimental design, data analysis and interpretation; NO & RM antibody design and generation;
659 AC tick tissue experiments. All authors were involved in manuscript editing.

660

661 **References.**

- 662 Adams, Philip P., Carlos Flores Avile, Niko Popitsch, Ivana Bilusic, Renée Schroeder, Meghan
663 Lybecker, and Mollie W. Jewett. 2017. "In Vivo Expression Technology and 5' End
664 Mapping of the *Borrelia burgdorferi* Transcriptome Identify Novel RNAs Expressed
665 during Mammalian Infection." *Nucleic Acids Research* 45 (2): 775–92.
666 <https://doi.org/10.1093/nar/gkw1180>.
- 667 Babitzke, Paul, Ying-Jung Lai, Andrew J. Renda, and Tony Romeo. 2019. "Posttranscription
668 Initiation Control of Gene Expression Mediated by Bacterial RNA-Binding Proteins."
669 *Annual Review of Microbiology* 73 (1): 43–67. [https://doi.org/10.1146/annurev-micro-
670 020518-115907](https://doi.org/10.1146/annurev-micro-020518-115907).
- 671 Barbour, A. G. 1984. "Isolation and Cultivation of Lyme Disease Spirochetes." *The Yale Journal*
672 *of Biology and Medicine* 57 (4): 521–25.
- 673 Bilusic, Ivana, Niko Popitsch, Philipp Rescheneder, Renée Schroeder, and Meghan Lybecker.
674 2014. "Revisiting the Coding Potential of the *E. Coli* Genome through Hfq Co-
675 Immunoprecipitation." *RNA Biology* 11 (5): 641–54. <https://doi.org/10.4161/rna.29299>.
- 676 Blevins, J. S., A. T. Revel, A. H. Smith, G. N. Bachlani, and M. V. Norgard. 2007. "Adaptation of a
677 Luciferase Gene Reporter and Lac Expression System to *Borrelia burgdorferi*." *Appl*
678 *Environ Microbiol* 73 (5): 1501–13.
- 679 Blevins, Jon S., Haijun Xu, Ming He, Michael V. Norgard, Larry Reitzer, and X. Frank Yang. 2009.
680 "Rrp2, a Σ 54-Dependent Transcriptional Activator of *Borrelia burgdorferi*, Activates RpoS
681 in an Enhancer-Independent Manner." *Journal of Bacteriology* 191 (8): 2902–5.
682 <https://doi.org/10.1128/JB.01721-08>.
- 683 Bontemps-Gallo, Sébastien, Kevin Lawrence, and Frank C. Gherardini. 2016. "Two Different
684 Virulence-Related Regulatory Pathways in *Borrelia burgdorferi* Are Directly Affected by
685 Osmotic Fluxes in the Blood Meal of Feeding Ixodes Ticks." *PLoS Pathogens* 12 (8):
686 e1005791. <https://doi.org/10.1371/journal.ppat.1005791>.
- 687 Botsford, J. L., and J. G. Harman. 1992. "Cyclic AMP in Prokaryotes." *Microbiology and*
688 *Molecular Biology Reviews* 56 (1): 100–122.
- 689 Boylan, J. A., C. S. Hummel, S. Benoit, J. Garcia-Lara, J. Treglown-Downey, E. J. Crane, and F. C.
690 Gherardini. 2006. "*Borrelia burgdorferi* Bb0728 Encodes a Coenzyme A Disulphide
691 Reductase Whose Function Suggests a Role in Intracellular Redox and the Oxidative
692 Stress Response." *Mol Microbiol* 59 (2): 475–86.
- 693 Boylan, J. A., K. A. Lawrence, J. S. Downey, and F. C. Gherardini. 2008. "*Borrelia burgdorferi*
694 Membranes Are the Primary Targets of Reactive Oxygen Species." *Mol Microbiol* 68 (3):
695 786–99.
- 696 Boylan, J. A., J. E. Posey, and F. C. Gherardini. 2003. "*Borrelia* Oxidative Stress Response
697 Regulator, BosR: A Distinctive Zn-Dependent Transcriptional Activator." *Proc Natl Acad*
698 *Sci U S A* 100 (20): 11684–89.
- 699 Caimano, M. J., C. H. Eggers, K. R. Hazlett, and J. D. Radolf. 2004. "RpoS Is Not Central to the
700 General Stress Response in *Borrelia burgdorferi* but Does Control Expression of One or
701 More Essential Virulence Determinants." *Infect Immun* 72 (11): 6433–45.
- 702 Caimano, M. J., R. Iyer, C. H. Eggers, C. Gonzalez, E. A. Morton, M. A. Gilbert, I. Schwartz, and J.
703 D. Radolf. 2007. "Analysis of the RpoS Regulon in *Borrelia burgdorferi* in Response to

- 704 Mammalian Host Signals Provides Insight into RpoS Function during the Enzoitic Cycle.”
705 *Mol Microbiol* 65 (5): 1193–1217.
- 706 Caimano, Melissa J., Star Dunham-Ems, Anna M. Allard, Maria B. Cassera, Melisha Kenedy, and
707 Justin D. Radolf. 2015. “C-Di-GMP Modulates Gene Expression in Lyme Disease
708 Spirochetes at the Tick-Mammal Interface to Promote Spirochete Survival during the
709 Blood Meal and Tick-to-Mammal Transmission.” *Infection and Immunity*, May.
710 <https://doi.org/10.1128/IAI.00315-15>.
- 711 Caimano, Melissa J., Christian H. Eggers, Cynthia A. Gonzalez, and Justin D. Radolf. 2005.
712 “Alternate Sigma Factor RpoS Is Required for the In Vivo-Specific Repression of *Borrelia*
713 *Burgdorferi* Plasmid Lp54-Borne OspA and Lp6.6 Genes.” *Journal of Bacteriology* 187
714 (22): 7845–52. <https://doi.org/10.1128/JB.187.22.7845-7852.2005>.
- 715 Caimano, Melissa J., Ashley M. Groshong, Alexia Belperron, Jialing Mao, Kelly L. Hawley, Amit
716 Luthra, Danielle E. Graham, et al. 2019. “The RpoS Gatekeeper in *Borrelia Burgdorferi*:
717 An Invariant Regulatory Scheme That Promotes Spirochete Persistence in Reservoir
718 Hosts and Niche Diversity.” *Frontiers in Microbiology* 10.
719 <https://doi.org/10.3389/fmicb.2019.01923>.
- 720 Caimano, Melissa J., Radha Iyer, Christian H. Eggers, Cynthia Gonzalez, Elizabeth A. Morton,
721 Michael A. Gilbert, Ira Schwartz, and Justin D. Radolf. 2007. “Analysis of the RpoS
722 Regulon in *Borrelia Burgdorferi* in Response to Mammalian Host Signals Provides Insight
723 into RpoS Function during the Enzoitic Cycle.” *Molecular Microbiology* 65 (5): 1193–
724 1217. <https://doi.org/10.1111/j.1365-2958.2007.05860.x>.
- 725 Cann, Martin J., Arne Hammer, Jie Zhou, and Tobias Kanacher. 2003. “A Defined Subset of
726 Adenylyl Cyclases Is Regulated by Bicarbonate Ion*.” *Journal of Biological Chemistry* 278
727 (37): 35033–38. <https://doi.org/10.1074/jbc.M303025200>.
- 728 Carroll, J. A., R. M. Cordova, and C. F. Garon. 2000. “Identification of 11 PH-Regulated Genes in
729 *Borrelia Burgdorferi* Localizing to Linear Plasmids.” *Infect Immun* 68 (12): 6677–84.
- 730 Carroll, J. A., C. F. Garon, and T. G. Schwan. 1999. “Effects of Environmental PH on Membrane
731 Proteins in *Borrelia Burgdorferi*.” *Infect Immun* 67 (7): 3181–87.
- 732 Casjens, S., N. Palmer, R. van Vugt, W. M. Huang, B. Stevenson, P. Rosa, R. Lathigra, et al. 2000.
733 “A Bacterial Genome in Flux: The Twelve Linear and Nine Circular Extrachromosomal
734 DNAs in an Infectious Isolate of the Lyme Disease Spirochete *Borrelia Burgdorferi*.” *Mol*
735 *Microbiol* 35 (3): 490–516.
- 736 Cugini, C., M. Medrano, T. G. Schwan, and J. Coburn. 2003. “Regulation of Expression of the
737 *Borrelia Burgdorferi* Beta(3)-Chain Integrin Ligand, P66, in Ticks and in Culture.” *Infect*
738 *Immun* 71 (2): 1001–7.
- 739 Curtiss, R., and S. M. Kelly. 1987. “*Salmonella Typhimurium* Deletion Mutants Lacking Adenylate
740 Cyclase and Cyclic AMP Receptor Protein Are Avirulent and Immunogenic.” *Infection and*
741 *Immunity* 55 (12): 3035–43.
- 742 Dong, Qing, Xufan Yan, Minhui Zheng, and Ziwen Yang. 2013. “Comparison of Two Type IV
743 Hyperthermophilic Adenylyl Cyclases Characterizations from the Archaeon *Pyrococcus*
744 *Furiosus*.” *Journal of Molecular Catalysis B: Enzymatic* 88 (April): 7–13.
745 <https://doi.org/10.1016/j.molcatb.2012.10.017>.
- 746 Drecktrah, Dan, Laura S. Hall, Philipp Rescheneder, Meghan Lybecker, and D. Scott Samuels.
747 2018. “The Stringent Response-Regulated SRNA Transcriptome of *Borrelia Burgdorferi*.”

- 748 *Frontiers in Cellular and Infection Microbiology* 8: 231.
749 <https://doi.org/10.3389/fcimb.2018.00231>.
- 750 Elias, Abdallah F., James L. Bono, John J. Kupko Iii, Philip E. Stewart, Jonathan G. Krum, and
751 Patricia A. Rosa. 2003. "New Antibiotic Resistance Cassettes Suitable for Genetic Studies
752 in *Borrelia burgdorferi*." *Journal of Molecular Microbiology and Biotechnology* 6 (1): 29–
753 40. <https://doi.org/10.1159/000073406>.
- 754 Franchini, Alessandro G., Julian Ihssen, and Thomas Egli. 2015. "Effect of Global Regulators
755 RpoS and Cyclic-AMP/CRP on the Catabolome and Transcriptome of *Escherichia coli* K12
756 during Carbon- and Energy-Limited Growth." *PLoS One* 10 (7): e0133793.
757 <https://doi.org/10.1371/journal.pone.0133793>.
- 758 Freedman, John C., Elizabeth A. Rogers, Jessica L. Kostick, Hongming Zhang, Radha Iyer, Ira
759 Schwartz, and Richard T. Marconi. 2010. "Identification and Molecular Characterization
760 of a Cyclic-Di-GMP Effector Protein, PlzA (BB0733): Additional Evidence for the Existence
761 of a Functional Cyclic-Di-GMP Regulatory Network in the Lyme Disease Spirochete,
762 *Borrelia burgdorferi*." *FEMS Immunology and Medical Microbiology* 58 (2): 285–94.
763 <https://doi.org/10.1111/j.1574-695X.2009.00635.x>.
- 764 Gallagher, D. Travis, Natasha N. Smith, Sook-Kyung Kim, Annie Heroux, Howard Robinson, and
765 Prasad T. Reddy. 2006. "Structure of the Class IV Adenylyl Cyclase Reveals a Novel Fold."
766 *Journal of Molecular Biology* 362 (1): 114–22.
767 <https://doi.org/10.1016/j.jmb.2006.07.008>.
- 768 Gottesman, Susan, and Gisela Storz. 2011. "Bacterial Small RNA Regulators: Versatile Roles and
769 Rapidly Evolving Variations." *Cold Spring Harbor Perspectives in Biology* 3 (12).
770 <https://doi.org/10.1101/cshperspect.a003798>.
- 771 Gstrein-Reider, E, and M Schweiger. 1982. "Regulation of Adenylyl Cyclase in *E. coli*." *The*
772 *EMBO Journal* 1 (3): 333–37.
- 773 Guo, B. P., E. L. Brown, D. W. Dorward, L. C. Rosenberg, and M. Hook. 1998. "Decorin-Binding
774 Adhesins from *Borrelia burgdorferi*." *Mol Microbiol* 30 (4): 711–23.
- 775 He, Ming, Bethany K. Boardman, Dalai Yan, and X. Frank Yang. 2007. "Regulation of Expression
776 of the Fibronectin-Binding Protein BBK32 in *Borrelia burgdorferi*." *Journal of*
777 *Bacteriology* 189 (22): 8377–80. <https://doi.org/10.1128/JB.01199-07>.
- 778 He, Ming, Zhiming Ouyang, Bryan Troxell, Haijun Xu, Akira Moh, Joseph Piesman, Michael V.
779 Norgard, Mark Gomelsky, and X. Frank Yang. 2011. "Cyclic Di-GMP Is Essential for the
780 Survival of the Lyme Disease Spirochete in Ticks." *PLOS Pathogens* 7 (6): e1002133.
781 <https://doi.org/10.1371/journal.ppat.1002133>.
- 782 He, Ming, Jun-Jie Zhang, Meiping Ye, Yongliang Lou, and X. Frank Yang. 2014. "Cyclic Di-GMP
783 Receptor PlzA Controls Virulence Gene Expression through RpoS in *Borrelia*
784 *burgdorferi*." *Infection and Immunity* 82 (1): 445–52. [https://doi.org/10.1128/IAI.01238-](https://doi.org/10.1128/IAI.01238-13)
785 13.
- 786 Hoffmaster, A. R., and T. M. Koehler. 1997. "The Anthrax Toxin Activator Gene *AtxA* Is
787 Associated with CO₂-Enhanced Non-Toxin Gene Expression in *Bacillus anthracis*." *Infect*
788 *Immun* 65 (8): 3091–99.
- 789 Hu, Linden T. 2016. "Lyme Disease." *Annals of Internal Medicine* 165 (9): 677.
790 <https://doi.org/10.7326/L16-0409>.

- 791 Hübner, A., X. Yang, D. M. Nolen, T. G. Popova, F. C. Cabello, and M. V. Norgard. 2001.
792 “Expression of *Borrelia burgdorferi* OspC and DbpA Is Controlled by a RpoN-RpoS
793 Regulatory Pathway.” *Proceedings of the National Academy of Sciences of the United*
794 *States of America* 98 (22): 12724–29. <https://doi.org/10.1073/pnas.231442498>.
- 795 Hyde, Jenny A., Dana K. Shaw, Roger Smith Iii, Jerome P. Trzeciakowski, and Jon T. Skare. 2009.
796 “The BosR Regulatory Protein of *Borrelia burgdorferi* Interfaces with the RpoS
797 Regulatory Pathway and Modulates Both the Oxidative Stress Response and Pathogenic
798 Properties of the Lyme Disease Spirochete.” *Molecular Microbiology* 74 (6): 1344–55.
799 <https://doi.org/10.1111/j.1365-2958.2009.06951.x>.
- 800 Hyde, Jenny A., Dana K. Shaw, Roger Smith, Jerome P. Trzeciakowski, and Jon T. Skare. 2010.
801 “Characterization of a Conditional BosR Mutant in *Borrelia burgdorferi*” 78 (1): 265–74.
802 <https://doi.org/10.1128/IAI.01018-09>.
- 803 Hyde, Jenny A., and Jon T. Skare. 2018. “Detection of Bioluminescent *Borrelia burgdorferi* from
804 In Vitro Cultivation and During Murine Infection.” *Methods in Molecular Biology (Clifton,*
805 *N.J.)* 1690: 241–57. https://doi.org/10.1007/978-1-4939-7383-5_18.
- 806 Hyde, Jenny A., Jerome P. Trzeciakowski, and Jonathan T. Skare. 2007. “*Borrelia burgdorferi*
807 Alters Its Gene Expression and Antigenic Profile in Response to CO₂ Levels.” *Journal of*
808 *Bacteriology* 189 (2): 437–45. <https://doi.org/10.1128/JB.01109-06>.
- 809 Hyde, Jenny A., Eric H. Weening, MiHee Chang, Jerome P. Trzeciakowski, Magnus Höök, Jeffrey
810 D. Cirillo, and Jon T. Skare. 2011. “Bioluminescent Imaging of *Borrelia burgdorferi* in Vivo
811 Demonstrates That the Fibronectin-Binding Protein BBK32 Is Required for Optimal
812 Infectivity.” *Molecular Microbiology* 82 (1): 99–113. [https://doi.org/10.1111/j.1365-](https://doi.org/10.1111/j.1365-2958.2011.07801.x)
813 [2958.2011.07801.x](https://doi.org/10.1111/j.1365-2958.2011.07801.x).
- 814 Hyde, Jenny A., Eric H. Weening, and Jon T. Skare. 2011. “Genetic Transformation of *Borrelia*
815 *burgdorferi*.” *Current Protocols in Microbiology* 20 (1): 12C.4.1-12C.4.17.
816 <https://doi.org/10.1002/9780471729259.mc12c04s20>.
- 817 Iosub, Ira Alexandra, Robert Willem van Nues, Stuart William McKellar, Karen Jule Nieken,
818 Marta Marchioretto, Brandon Sy, Jai Justin Tree, Gabriella Viero, and Sander
819 Granneman. 2020. “Hfq CLASH Uncovers SRNA-Target Interaction Networks Linked to
820 Nutrient Availability Adaptation.” Edited by Joseph T Wade, James L Manley, and Ben F
821 Luisi. *ELife* 9 (May): e54655. <https://doi.org/10.7554/eLife.54655>.
- 822 Izac, Jerilyn R., Andrew C. Camire, Christopher G. Earnhart, Monica E. Embers, Rebecca A. Funk,
823 Edward B. Breitschwerdt, and Richard T. Marconi. 2019. “Analysis of the Antigenic
824 Determinants of the OspC Protein of the Lyme Disease Spirochetes: Evidence That the
825 C10 Motif Is Not Immunodominant or Required to Elicit Bactericidal Antibody
826 Responses.” *Vaccine* 37 (17): 2401–7. <https://doi.org/10.1016/j.vaccine.2019.02.007>.
- 827 Kamenetsky, Margarita, Sabine Middelhaufe, Erin M. Bank, Lonny R. Levin, Jochen Buck, and
828 Clemens Steegborn. 2006. “Molecular Details of CAMP Generation in Mammalian Cells:
829 A Tale of Two Systems.” *Journal of Molecular Biology* 362 (4): 623–39.
830 <https://doi.org/10.1016/j.jmb.2006.07.045>.
- 831 Kawabata, H., S. J. Norris, and H. Watanabe. 2004. “BBE02 Disruption Mutants of *Borrelia*
832 *burgdorferi* B31 Have a Highly Transformable, Infectious Phenotype.” *Infect Immun* 72
833 (12): 7147–54.

- 834 Khajanchi, Bijay K., Evelyn Odeh, Lihui Gao, Mary B. Jacobs, Mario T. Philipp, Tao Lin, and Steven
835 J. Norris. 2016. "Phosphoenolpyruvate Phosphotransferase System Components
836 Modulate Gene Transcription and Virulence of *Borrelia burgdorferi*." *Infection and
837 Immunity* 84 (3): 754–64. <https://doi.org/10.1128/IAI.00917-15>.
- 838 Konkel, M. E., and K. Tilly. 2000. "Temperature-Regulated Expression of Bacterial Virulence
839 Genes." *Microbes Infect* 2 (2): 157–66.
- 840 Kostick, Jessica L., Lee T. Szkotnicki, Elizabeth A. Rogers, Paola Bocci, Nadia Raffaelli, and
841 Richard T. Marconi. 2011. "The Diguanylate Cyclase, Rrp1, Regulates Critical Steps in the
842 Enzootic Cycle of the Lyme Disease Spirochetes." *Molecular Microbiology* 81 (1): 219–
843 31. <https://doi.org/10.1111/j.1365-2958.2011.07687.x>.
- 844 Kostick-Dunn, Jessica L., Jerilyn R. Izac, John C. Freedman, Lee T. Szkotnicki, Lee D. Oliver, and
845 Richard T. Marconi. 2018. "The *Borrelia burgdorferi* C-Di-GMP Binding Receptors, PlzA
846 and PlzB, Are Functionally Distinct." *Frontiers in Cellular and Infection Microbiology* 8:
847 213. <https://doi.org/10.3389/fcimb.2018.00213>.
- 848 Labandeira-Rey, M., and J. T. Skare. 2001. "Decreased Infectivity in *Borrelia burgdorferi* Strain
849 B31 Is Associated with Loss of Linear Plasmid 25 or 28-1." *Infection and Immunity* 69 (1):
850 446–55. <https://doi.org/10.1128/IAI.69.1.446-455.2001>.
- 851 Lackum, Kate von, and Brian Stevenson. 2005. "Carbohydrate Utilization by the Lyme Borreliosis
852 Spirochete, *Borrelia burgdorferi*." *FEMS Microbiology Letters* 243 (1): 173–79.
853 <https://doi.org/10.1016/j.femsle.2004.12.002>.
- 854 Lawrenz, M. B., H. Kawabata, J. E. Purser, and S. J. Norris. 2002. "Decreased Electroporation
855 Efficiency in *Borrelia burgdorferi* Containing Linear Plasmids Lp25 and Lp56: Impact on
856 Transformation of Infectious *B. burgdorferi*." *Infect Immun* 70 (9): 4798–4804.
- 857 Li, X., U. Pal, N. Ramamoorthi, X. Liu, D. C. Desrosiers, C. H. Eggers, J. F. Anderson, J. D. Radolf,
858 and E. Fikrig. 2007. "The Lyme Disease Agent *Borrelia burgdorferi* Requires BB0690, a
859 Dps Homologue, to Persist within Ticks." *Mol Microbiol* 63 (3): 694–710.
- 860 Liang, Weili, Alberto Pascual-Montano, Anisia J. Silva, and Jorge A. Benitez. 2007. "The Cyclic
861 AMP Receptor Protein Modulates Quorum Sensing, Motility and Multiple Genes That
862 Affect Intestinal Colonization in *Vibrio Cholerae*." *Microbiology*, 153 (9): 2964–75.
863 <https://doi.org/10.1099/mic.0.2007/006668-0>.
- 864 Liu, Cong, Di Sun, Jingrong Zhu, Jiawen Liu, and Weijie Liu. 2020. "The Regulation of Bacterial
865 Biofilm Formation by CAMP-CRP: A Mini-Review." *Frontiers in Microbiology* 11.
866 <https://doi.org/10.3389/fmicb.2020.00802>.
- 867 Livak, K. J., and T. D. Schmittgen. 2001. "Analysis of Relative Gene Expression Data Using Real-
868 Time Quantitative PCR and the 2^{-Delta Delta C(T)} Method." *Methods (San Diego, Calif.)*
869 25 (4): 402–8. <https://doi.org/10.1006/meth.2001.1262>.
- 870 Livengood, Jill A., Virginia L. Schmit, and Robert D. Gilmore. 2008. "Global Transcriptome
871 Analysis of *Borrelia burgdorferi* during Association with Human Neuroglial Cells."
872 *Infection and Immunity* 76 (1): 298–307. <https://doi.org/10.1128/IAI.00866-07>.
- 873 Lybecker, M., and KC Henderson. 2018. "*Borrelia burgdorferi* Transcriptome Analysis by RNA-
874 Sequencing." In *Borrelia burgdorferi: Methods and Protocols*, edited by Utpal Pal and
875 Ozlem Buyuktanir, 127–36. Methods in Molecular Biology. New York, NY: Springer.
- 876 Lybecker, Meghan, Bob Zimmermann, Ivana Bilusic, Nadezda Tukhtubaeva, and Renée
877 Schroeder. 2014. "The Double-Stranded Transcriptome of *Escherichia coli*." *Proceedings*

- 878 *of the National Academy of Sciences of the United States of America* 111 (8): 3134–39.
879 <https://doi.org/10.1073/pnas.1315974111>.
- 880 Mallory, Katherine L., Daniel P. Miller, Lee D. Oliver, John C. Freedman, Jessica L. Kostick-Dunn,
881 Jason A. Carlyon, James D. Marion, Jessica K. Bell, and Richard T. Marconi. 2016. “Cyclic-
882 Di-GMP Binding Induces Structural Rearrangements in the PlzA and PlzC Proteins of the
883 Lyme Disease and Relapsing Fever Spirochetes: A Possible Switch Mechanism for c-Di-
884 GMP-Mediated Effector Functions.” *Pathogens and Disease* 74 (8).
885 <https://doi.org/10.1093/femspd/ftw105>.
- 886 Maruskova, Mahulena, M. Dolores Esteve-Gassent, Valerie L. Sexton, and J. Seshu. 2008. “Role
887 of the BBA64 Locus of *Borrelia burgdorferi* in Early Stages of Infectivity in a Murine
888 Model of Lyme Disease.” *Infection and Immunity* 76 (1): 391–402.
889 <https://doi.org/10.1128/IAI.01118-07>.
- 890 McDonough, Kathleen A., and Ana Rodriguez. 2011. “The Myriad Roles of Cyclic AMP in
891 Microbial Pathogens: From Signal to Sword.” *Nature Reviews Microbiology* 10
892 (November): 27.
- 893 Melamed, Sahar, Philip P. Adams, Aixia Zhang, Hongen Zhang, and Gisela Storz. 2020. “RNA-
894 RNA Interactomes of ProQ and Hfq Reveal Overlapping and Competing Roles.”
895 *Molecular Cell* 77 (2): 411–425.e7. <https://doi.org/10.1016/j.molcel.2019.10.022>.
- 896 Melamed, Sahar, Asaf Peer, Raya Faigenbaum-Romm, Yair E. Gatt, Niv Reiss, Amir Bar, Yael
897 Altuvia, Liron Argaman, and Hanah Margalit. 2016. “Global Mapping of Small RNA-
898 Target Interactions in Bacteria.” *Molecular Cell* 63 (5): 884–97.
899 <https://doi.org/10.1016/j.molcel.2016.07.026>.
- 900 Miller, Christine L., S. L. Rajasekhar Karna, and J. Seshu. 2013. “*Borrelia* Host Adaptation
901 Regulator (BadR) Regulates RpoS to Modulate Host Adaptation and Virulence Factors in
902 *Borrelia burgdorferi*.” *Molecular Microbiology* 88 (1): 105–24.
903 <https://doi.org/10.1111/mmi.12171>.
- 904 Miller, Daniel P., Lee D. Oliver, Brittney K. Tegels, Lucas A. Reed, Nathaniel S. O’Bier, Kurni
905 Kurniyati, Lindsay A. Faust, et al. 2016. “The *Treponema denticola* FhbB Protein Is a
906 Dominant Early Antigen That Elicits FhbB Variant-Specific Antibodies That Block Factor H
907 Binding and Cleavage by Dentilisin.” *Infection and Immunity* 84 (7): 2051–58.
908 <https://doi.org/10.1128/IAI.01542-15>.
- 909 Molina-Quiroz, Roberto C., Cecilia Silva-Valenzuela, Jennifer Brewster, Eduardo Castro-Nallar,
910 Stuart B. Levy, and Andrew Camilli. 2018. “Cyclic AMP Regulates Bacterial Persistence
911 through Repression of the Oxidative Stress Response and SOS-Dependent DNA Repair in
912 Uropathogenic *Escherichia coli*.” *MBio* 9 (1). <https://doi.org/10.1128/mBio.02144-17>.
- 913 Mouali, Youssef El, Tania Gaviria-Cantin, María Antonia Sánchez-Romero, Marta Gibert,
914 Alexander J. Westermann, Jörg Vogel, and Carlos Balsalobre. 2018. “CRP-CAMP
915 Mediates Silencing of *Salmonella* Virulence at the Post-Transcriptional Level.” *PLOS*
916 *Genetics* 14 (6): e1007401. <https://doi.org/10.1371/journal.pgen.1007401>.
- 917 Novak, Elizabeth A., Syed Z. Sultan, and Md A. Motaleb. 2014. “The Cyclic-Di-GMP Signaling
918 Pathway in the Lyme Disease Spirochete, *Borrelia burgdorferi*.” *Frontiers in Cellular and*
919 *Infection Microbiology* 4: 56. <https://doi.org/10.3389/fcimb.2014.00056>.
- 920 Oliver, J. H., F. W. Chandler, M. P. Luttrell, A. M. James, D. E. Stallknecht, B. S. McGuire, H. J.
921 Hutcheson, G. A. Cummins, and R. S. Lane. 1993. “Isolation and Transmission of the


- 922 Lyme Disease Spirochete from the Southeastern United States." *Proceedings of the*
923 *National Academy of Sciences of the United States of America* 90 (15): 7371–75.
- 924 Oliver, Jonathan D., Adela S. Oliva Chávez, Roderick F. Felsheim, Timothy J. Kurtti, and Ulrike G.
925 Munderloh. 2015. "An Ixodes Scapularis Cell Line with a Predominantly Neuron-like
926 Phenotype." *Experimental & Applied Acarology* 66 (3): 427–42.
927 <https://doi.org/10.1007/s10493-015-9908-1>.
- 928 Ouyang, Z., J. S. Blevins, and M. V. Norgard. 2008. "Transcriptional Interplay among the
929 Regulators Rrp2, RpoN and RpoS in *Borrelia Burgdorferi*." *Microbiology (Reading,*
930 *England)* 154 (Pt 9): 2641–58.
- 931 Ouyang, Zhiming, Ranjit K. Deka, and Michael V. Norgard. 2011. "BosR (BB0647) Controls the
932 RpoN-RpoS Regulatory Pathway and Virulence Expression in *Borrelia Burgdorferi* by a
933 Novel DNA-Binding Mechanism." *PLOS Pathogens* 7 (2): e1001272.
934 <https://doi.org/10.1371/journal.ppat.1001272>.
- 935 Ouyang, Zhiming, Manish Kumar, Toru Kariu, Shayma Haq, Martin Goldberg, Utpal Pal, and
936 Michael V. Norgard. 2009. "BosR (BB0647) Governs Virulence Expression in *Borrelia*
937 *Burgdorferi*." *Molecular Microbiology* 74 (6): 1331–43. [https://doi.org/10.1111/j.1365-](https://doi.org/10.1111/j.1365-2958.2009.06945.x)
938 [2958.2009.06945.x](https://doi.org/10.1111/j.1365-2958.2009.06945.x).
- 939 Papenfort, Kai, and Jörg Vogel. 2010. "Regulatory RNA in Bacterial Pathogens." *Cell Host &*
940 *Microbe* 8 (1): 116–27. <https://doi.org/10.1016/j.chom.2010.06.008>.
- 941 Peterkofsky, Alan, and Celia Gazdar. 1974. "Glucose Inhibition of Adenylate Cyclase in Intact
942 Cells of *Escherichia Coli* B." *Proceedings of the National Academy of Sciences of the*
943 *United States of America* 71 (6): 2324–28.
- 944 Popitsch, Niko, Ivana Bilusic, Philipp Rescheneder, Renée Schroeder, and Meghan Lybecker.
945 2017. "Temperature-Dependent SRNA Transcriptome of the Lyme Disease Spirochete."
946 *BMC Genomics* 18 (January). <https://doi.org/10.1186/s12864-016-3398-3>.
- 947 Purificação, Aline Dias da, Nathalia Marins de Azevedo, Gabriel Guarany de Araujo, Robson
948 Francisco de Souza, and Cristiane Rodrigues Guzzo. 2020. "The World of Cyclic
949 Dinucleotides in Bacterial Behavior." *Molecules* 25 (10): 2462.
950 <https://doi.org/10.3390/molecules25102462>.
- 951 Radolf, Justin D, Melissa J Caimano, Brian Stevenson, and Linden T Hu. 2012. "Of Ticks, Mice
952 and Men: Understanding the Dual-Host Lifestyle of Lyme Disease Spirochaetes." *Nature*
953 *Reviews. Microbiology* 10 (2): 87–99. <https://doi.org/10.1038/nrmicro2714>.
- 954 Ramsey, Meghan E., Jenny A. Hyde, Diana N. Medina-Perez, Tao Lin, Lihui Gao, Maureen E.
955 Lundt, Xin Li, Steven J. Norris, Jon T. Skare, and Linden T. Hu. 2017. "A High-Throughput
956 Genetic Screen Identifies Previously Uncharacterized *Borrelia Burgdorferi* Genes
957 Important for Resistance against Reactive Oxygen and Nitrogen Species." *PLOS*
958 *Pathogens* 13 (2): e1006225. <https://doi.org/10.1371/journal.ppat.1006225>.
- 959 Rebollo-Ramirez, Sonia, and Gerald Larrouy-Maumus. 2019. "NaCl Triggers the CRP-Dependent
960 Increase of CAMP in *Mycobacterium Tuberculosis*." *Tuberculosis (Edinburgh, Scotland)*
961 116: 8–16. <https://doi.org/10.1016/j.tube.2019.03.009>.
- 962 Rogers, Elizabeth A., Darya Terekhova, Hong-Ming Zhang, Kelley M. Hovis, Ira Schwartz, and
963 Richard T. Marconi. 2009. "Rrp1, a Cyclic-Di-GMP-Producing Response Regulator, Is an
964 Important Regulator of *Borrelia Burgdorferi* Core Cellular Functions." *Molecular*
965 *Microbiology* 71 (6): 1551–73. <https://doi.org/10.1111/j.1365-2958.2009.06621.x>.

- 966 Rosenberg, Ronald. 2018. "Vital Signs: Trends in Reported Vectorborne Disease Cases — United
967 States and Territories, 2004–2016." *MMWR. Morbidity and Mortality Weekly Report* 67.
968 <https://doi.org/10.15585/mmwr.mm6717e1>.
- 969 Samuels, D S, K E Mach, and C F Garon. 1994. "Genetic Transformation of the Lyme Disease
970 Agent *Borrelia Burgdorferi* with Coumarin-Resistant GyrB." *Journal of Bacteriology* 176
971 (19): 6045–49.
- 972 Samuels, D. Scott, and Leah R. N. Samuels. 2016. "Gene Regulation During the Enzootic Cycle of
973 the Lyme Disease Spirochete." *Forum on Immunopathological Diseases and Therapeutics*
974 7 (3–4): 205–12. <https://doi.org/10.1615/ForumImmDisTher.2017019469>.
- 975 Saputra, Elizabeth P., Jerome P. Trzeciakowski, and Jenny A. Hyde. 2020. "Borrelia Burgdorferi
976 Spatiotemporal Regulation of Transcriptional Regulator BosR and Decorin Binding
977 Protein during Murine Infection." *Scientific Reports* 10 (1): 12534.
978 <https://doi.org/10.1038/s41598-020-69212-7>.
- 979 Savage, Christina R., William K. Arnold, Alexandra Gjevre-Nail, Benjamin J. Koestler, Eric L.
980 Bruger, Jeffrey R. Barker, Christopher M. Waters, and Brian Stevenson. 2015.
981 "Intracellular Concentrations of *Borrelia Burgdorferi* Cyclic Di-AMP Are Not Changed by
982 Altered Expression of the CdaA Synthase." *PLoS One* 10 (4): e0125440.
983 <https://doi.org/10.1371/journal.pone.0125440>.
- 984 Schmit, Virginia L., Toni G. Patton, and Robert D. Gilmore. 2011. "Analysis of *Borrelia*
985 *Burgdorferi* Surface Proteins as Determinants in Establishing Host Cell Interactions."
986 *Frontiers in Microbiology* 2: 141. <https://doi.org/10.3389/fmicb.2011.00141>.
- 987 Seshu, J., J. A. Boylan, F. C. Gherardini, and J. T. Skare. 2004. "Dissolved Oxygen Levels Alter
988 Gene Expression and Antigen Profiles in *Borrelia Burgdorferi*." *Infect Immun* 72 (3):
989 1580–86.
- 990 Seshu, J., J. A. Boylan, J. A. Hyde, K. L. Swingle, F. C. Gherardini, and J. T. Skare. 2004. "A
991 Conservative Amino Acid Change Alters the Function of BosR, the Redox Regulator of
992 *Borrelia Burgdorferi*." *Mol Microbiol* 54 (5): 1352–63.
- 993 Sismeiro, O., P. Trotot, F. Biville, C. Vivares, and A. Danchin. 1998. "Aeromonas Hydrophila
994 Adenylyl Cyclase 2: A New Class of Adenylyl Cyclases with Thermophilic Properties and
995 Sequence Similarities to Proteins from Hyperthermophilic Archaeobacteria." *Journal of*
996 *Bacteriology* 180 (13): 3339–44. <https://doi.org/10.1128/JB.180.13.3339-3344.1998>.
- 997 Smith, A. H., J. S. Blevins, G. N. Bachlani, X. F. Yang, and M. V. Norgard. 2007. "Evidence That
998 RpoS (SigmaS) in *Borrelia Burgdorferi* Is Controlled Directly by RpoN (Sigma54/SigmaN)."
999 *J Bacteriol* 189 (5): 2139–44.
- 1000 Smith, Natasha, Sook-Kyung Kim, Prasad T. Reddy, and D. Travis Gallagher. 2006.
1001 "Crystallization of the Class IV Adenylyl Cyclase from *Yersinia Pestis*." *Acta*
1002 *Crystallographica Section F: Structural Biology and Crystallization Communications* 62
1003 (Pt 3): 200–204. <https://doi.org/10.1107/S1744309106002855>.
- 1004 Smith, Roger S., Matthew C. Wolfgang, and Stephen Lory. 2004. "An Adenylate Cyclase-
1005 Controlled Signaling Network Regulates *Pseudomonas Aeruginosa* Virulence in a Mouse
1006 Model of Acute Pneumonia." *Infection and Immunity* 72 (3): 1677–84.
1007 <https://doi.org/10.1128/iai.72.3.1677-1684.2004>.


- 1008 Stanek, Gerold, and Franc Strle. 2018. "Lyme Borreliosis—from Tick Bite to Diagnosis and
1009 Treatment." *FEMS Microbiology Reviews* 42 (3): 233–58.
1010 <https://doi.org/10.1093/femsre/fux047>.
- 1011 Stanley McKnight, G. 1991. "Cyclic AMP Second Messenger Systems." *Current Opinion in Cell
1012 Biology* 3 (2): 213–17. [https://doi.org/10.1016/0955-0674\(91\)90141-K](https://doi.org/10.1016/0955-0674(91)90141-K).
- 1013 Steere, Allen C., Franc Strle, Gary P. Wormser, Linden T. Hu, John A. Branda, Joppe W. R. Hovius,
1014 Xin Li, and Paul S. Mead. 2016. "Lyme Borreliosis." *Nature Reviews. Disease Primers* 2:
1015 16090. <https://doi.org/10.1038/nrdp.2016.90>.
- 1016 Stevenson, B., T. G. Schwan, and P. A. Rosa. 1995. "Temperature-Related Differential Expression
1017 of Antigens in the Lyme Disease Spirochete, *Borrelia burgdorferi*." *Infection & Immunity*
1018 63 (11): 4535–39.
- 1019 Sultan, Syed Z., Joshua E. Pitzer, Tristan Boquoi, Gerry Hobbs, Michael R. Miller, and M. A.
1020 Motaleb. 2011. "Analysis of the HD-GYP Domain Cyclic Dimeric GMP Phosphodiesterase
1021 Reveals a Role in Motility and the Enzootic Life Cycle of *Borrelia burgdorferi*." *Infection
1022 and Immunity* 79 (8): 3273–83. <https://doi.org/10.1128/IAI.05153-11>.
- 1023 Sultan, Syed Z., Joshua E. Pitzer, Michael R. Miller, and Md A. Motaleb. 2010. "Analysis of a
1024 *Borrelia burgdorferi* Phosphodiesterase Demonstrates a Role for Cyclic-Di-Guanosine
1025 Monophosphate in Motility and Virulence." *Molecular Microbiology* 77 (1): 128–42.
1026 <https://doi.org/10.1111/j.1365-2958.2010.07191.x>.
- 1027 Tokarz, Rafal, Julie M. Anderton, Laura I. Katona, and Jorge L. Benach. 2004. "Combined Effects
1028 of Blood and Temperature Shift on *Borrelia burgdorferi* Gene Expression as Determined
1029 by Whole Genome DNA Array." *Infection and Immunity* 72 (9): 5419–32.
1030 <https://doi.org/10.1128/IAI.72.9.5419-5432.2004>.
- 1031 Wu, Jing, Eric H. Weening, Jennifer B. Faske, Magnus Höök, and Jon T. Skare. 2011. "Invasion of
1032 Eukaryotic Cells by *Borrelia burgdorferi* Requires B1 Integrins and Src Kinase Activity."
1033 *Infection and Immunity* 79 (3): 1338–48. <https://doi.org/10.1128/IAI.01188-10>.
- 1034 Yang, X. F., M. C. Lybecker, U. Pal, S. M. Alani, J. Blevins, A. T. Revel, D. S. Samuels, and M. V.
1035 Norgard. 2005. "Analysis of the OspC Regulatory Element Controlled by the RpoN-RpoS
1036 Regulatory Pathway in *Borrelia burgdorferi*." *J Bacteriol* 187 (14): 4822–29.
- 1037 Yang, X., M. S. Goldberg, T. G. Popova, G. B. Schoeler, S. K. Wikel, K. E. Hagman, and M. V.
1038 Norgard. 2000. "Interdependence of Environmental Factors Influencing Reciprocal
1039 Patterns of Gene Expression in Virulent *Borrelia burgdorferi*." *Mol Microbiol* 37 (6):
1040 1470-9.
- 1041 Yang, Xiaofeng F., Sophie M. Alani, and Michael V. Norgard. 2003. "The Response Regulator
1042 Rrp2 Is Essential for the Expression of Major Membrane Lipoproteins in *Borrelia
1043 burgdorferi*." *Proceedings of the National Academy of Sciences* 100 (19): 11001–6.
1044 <https://doi.org/10.1073/pnas.1834315100>.
- 1045 Ye, Meiping, Jun-Jie Zhang, Xin Fang, Gavin B. Lawlis, Bryan Troxell, Yan Zhou, Mark Gomelsky,
1046 Yongliang Lou, and X. Frank Yang. 2014. "DhhP, a Cyclic Di-AMP Phosphodiesterase of
1047 *Borrelia burgdorferi*, Is Essential for Cell Growth and Virulence." *Infection and Immunity*
1048 82 (5): 1840–49. <https://doi.org/10.1128/IAI.00030-14>.
- 1049 Yin, Wen, Xia Cai, Hongdan Ma, Li Zhu, Yuling Zhang, Shan-Ho Chou, Michael Y Galperin, and Jin
1050 He. 2020. "A Decade of Research on the Second Messenger C-Di-AMP." *FEMS
1051 Microbiology Reviews* 44 (6): 701–24. <https://doi.org/10.1093/femsre/fuaa019>.

1052 Zhang, Jun-Jie, Tong Chen, Youyun Yang, Jimei Du, Hongxia Li, Bryan Troxell, Ming He, Sebastian
1053 E. Carrasco, Mark Gomelsky, and X. Frank Yang. 2018. "Positive and Negative Regulation
1054 of Glycerol Utilization by the C-Di-GMP Binding Protein PlzA in *Borrelia burgdorferi*."
1055 *Journal of Bacteriology* 200 (22). <https://doi.org/10.1128/JB.00243-18>.



1056




A




B








A




B









A




B





C



D



● WT ■ *cyaB*⁻ ▲ *c-cyaB* ▼ *c-cyaB-SR0623* ◆ *c-cyaB-SR0623w*

A**B****C**